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San Diego and Stanford, California; New York, New York; Leiden, the Netherlands; Minneapolis, Minnesota;
Baltimore, Maryland; Cleveland, Ohio; and Portland, OregonAs in past years, this Highlights paper takes the place of the
Editor’s Page, and was assembled by the associate editors
based upon the papers that they perceived had or would have
the greatest impact upon cardiology. Space constraints result
in omitting many excellent papers, and we apologize in
advance to those authors.Transcatheter aortic valve replacement. Clinical, Doppler,
and outcome data were prospectively collected on 639 pa-
tients who underwent transcatheter aortic valve replacement
(TAVR) for symptomatic severe aortic stenosis (AS) in
2 Canadian centers (1). Compared with normal ﬂow pa-
tients, 52.3% had low ﬂow (stroke volume index <35 ml/m2)
and had increased 30-day all-cause mortality (11.4%
vs. 5.9%; p < 0.01), 2-year all-cause mortality (35.3% vs.
30.9%), and 2-year cardiovascular mortality (25.7% vs.
16.8%; p ¼ 0.01). Reduced ﬂow was an independent pre-
dictor of 30-day mortality, cumulative all-cause mortality,
and cumulative cardiovascular mortality. The study
concluded that stroke volume index should be integrated in
the risk stratiﬁcation process of these patients.
The PARTNER (Placement of Aortic Transcatheter
Valve) trial of the Edwards SAPIEN prosthesis (Edwards
Lifesciences, Irvine, California) examined the determinants
and outcomes of transcatheter valve embolization (TVE)
and/or acute insertion of a second prosthetic transcatheter
valve (TV) within the ﬁrst TV (TV-in-TV) in cohorts A and
B (2). Of 2,554 patients, 63 (2.47%) underwent TV-in-TV,
and 26 underwent (1.01%) TVE. The TV-in-TV was indi-
cated for aortic regurgitation (AR) in most patients, not only
because of malpositioning but also due to leaﬂet dysfunction,
and it was an independent predictor of 1-year cardiovascularFrom the *Cardiology Division, UCSD Medical Center, San Diego, California;
yLeiden UniversityMedical Center, Leiden, theNetherlands; zCardiovascular Research
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Diego, California; #Johns Hopkins Hospital, Baltimore, Maryland; **Department of
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Cardiology, Oregon Health and Science University, Portland, Oregon. All relationship
with industry information for each author is available on the JACC home page.mortality. Multivariable analysis found TVE to be an inde-
pendent predictor of 1-year mortality but not cardiovascular
mortality.
A meta-analysis determined the incidence, impact, and
predictors of post-TAVR AR in 45 studies reporting 12,926
patients, 5,261 with CoreValve (Medtronic, Minneapolis,
Minnesota) and 7,279 with Edwards valve. The pooled es-
timate for moderate or severe AR post-TAVR was 11.7%,
was more common with the CoreValve (16.0% vs. 9.1%; p ¼
0.005), and increased 30-day and 1-year mortality. Im-
plantation depth, valve undersizing, and Agatston calcium
score were identiﬁed as important predictors (3).
The 5-year outcomes after successful TAVR with a
balloon-expandable valve were evaluated in 88 patients (4).
Mean aortic valve gradient decreased from 46 to 10 mm Hg
after TAVR and was 11.8 mm Hg at 5 years (p for
trend ¼ 0.06). Mean aortic valve area increased from 0.62 to
1.67 cm2 after TAVI and was 1.40 cm2 at 5 years (p for
trend ¼ 0.01). Survival rates at 1 to 5 years were 83%, 74%,
53%, 42%, and 35%, respectively; and median survival time
was 3.4 years. The risk of death was signiﬁcantly increased
with chronic obstructive pulmonary and at least moderate
paravalvular AR.
A paper compared outcomes after transfemoral TAVR
with the Medtronic CoreValve versus the Edwards
SAPIEN/SAPIEN XT transcatheter heart valve for severe
AS using pooled databases of 4 experienced European
centers (5). After propensity matching, 204 patients were
identiﬁed in each group. At 30 days, there were no differ-
ences in all-cause mortality, cardiovascular mortality,
myocardial infarction (MI), stroke, device success, major
vascular complications, or life-threatening bleeding. The
Medtronic CoreValve was associated with more permanent
pacemakers (22.5% vs. 5.9%). At 1 year, there were no
differences in all-cause or cardiovascular mortality.
The technical feasibility and safety of the transaortic
TAVR was investigated in 44 consecutive patients with
inoperable, severe AS who were not eligible for transfemoral
access (6). Procedural and 30-day clinical outcomes were
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571compared with those of 76 patients who underwent trans-
apical TAVR, the current alternative route. Device success
and rates of 30-day combined safety endpoint of all-cause
mortality, MI, major stroke, disabling bleeding, severe
acute kidney injury, and valve reintervention were similar in
the transaortic and transapical TAVR groups. The trans-
aortic approach had a lower combined bleeding and vascular
event rate, shorter median intensive care unit length of stay,
and a favorable learning curve. TAVR through the trans-
aortic approach is technically feasible, seems to be associated
with favorable outcomes, and expands the current alternative
options for access sites in patients with inoperable aortic
stenosis who are ineligible for transfemoral TAVR.
Data from 642 consecutive patients who underwent
TAVI were prospectively collected, and patients were
grouped into chronic kidney disease (CKD) stages 1þ2, 3a,
3b, and 4 on the basis of estimated glomerular ﬁltration rate
(7). The 30-day and cumulative 1-year mortality rates
increased signiﬁcantly across the 4 groups. After adjustment
for confounders, CKD stage 4 was associated with increased
risk for 30-day mortality (hazard ratio [HR]: 3.04), and
CKD stages 3b and 4 were related to increased cumulative
1-year mortality (HR: 1.71 and 2.91, respectively) compared
with CKD stage 1þ2.
The results of transapicalmitral valve-in-valve implantation
were reported for 23 consecutive patients with severe mitral
bioprosthetic valve dysfunction (stenosis in 6, regurgitation in
9, and combined in 8) (8). Transapical valve-in-valve im-
plantation was successful in all patients using balloon
expandable valveswithout intraoperativemajor complications.
Mitral transvalvular gradient decreased from 11.1 to 6.9 mm
Hg after the procedure (p ¼ 0.01), and intervalvular regur-
gitation was absent (47.8%) or mild (52.2%). At a median
follow-up of 753 days, survival was 90.4%.
Three comprehensive reviews on TAVR were published
covering topics of paravalvular aortic regurgitation (PAR)
(9,10) and management of coronary artery disease (CAD) in
patients with severe AS referred for TAVR (11).
Fractional ﬂow reserve and instantaneous wave-free ratio.
Instantaneous wave-free ratio (iFR), a vasodilator-free pres-
sure-only measure of the hemodynamic severity of a coronary
stenosis, has been proposed as a new index of stenosis severity
that can be measured without adenosine. In the CLARIFY
(Classiﬁcation Accuracy of Pressure-Only Ratios Against
Indices Using Flow) study, hyperemic stenosis resistance
(HSR), a combined pressure-and-ﬂow index, was used as an
arbiter to determine when iFR and conventional fractional
ﬂow reserve (FFR) disagree and which index is most repre-
sentative of the hemodynamic signiﬁcance of the stenosis
(12). In 51 vessels, intracoronary pressure and ﬂow velocity
were measured distal to the stenosis at rest and during
adenosine-mediated hyperemia. The iFR, both at rest and
during adenosine administration (iFRa), FFR, HSR, baseline,
and hyperemic microvascular resistance were calculated using
automated algorithms. When iFR and FFR disagreed (4
cases, or 7.7% of the study population), HSR agreed with iFRin 50% of cases and with FFR in 50% of cases. Differences in
magnitude of microvascular resistance did not inﬂuence
diagnostic categorization; the iFR, iFRa, and FFR had
equally good diagnostic agreement with HSR (receiver-
operating characteristic area under the curve 0.93 iFR vs. 0.94
iFRa and 0.96 FFR). The researchers concluded that iFR and
FFR had equivalent agreement with classiﬁcation of coronary
stenosis severity by HSR. Further reduction in resistance
by the administration of adenosine did not improve diagnostic
categorization, indicating that iFR can be used as an
adenosine-free alternative to FFR.
In contrast, the VERIFY (Comparison of Fractional Flow
Reserve Versus Instant Wave-Free Ratio for Assessment
of Coronary Artery Stenosis Severity in Routine Practice)
study compared FFR with iFR in patients with CAD and
determined whether the iFR is independent of hyperemia
(13). In a prospective, multicenter, international study of 206
consecutive patients referred for percutaneous coronary
intervention (PCI) and a retrospective analysis of 500
archived pressure recordings, aortic and distal coronary
pressures were measured in duplicate in patients under
resting conditions and during intravenous adenosine infusion
at 140 mg/kg/min. Compared to the FFR cut-off value
of 0.80, the diagnostic accuracy of the iFR value of 0.80
was 60% (95% conﬁdence interval [CI]: 53% to 67%) for
all vessels studied, and 51% (95% CI: 43% to 59%) for pa-
tients with FFR in the range of 0.60 to 0.90. The iFR
was signiﬁcantly inﬂuenced by the induction of hyperemia:
mean iFR at rest was 0.82, versus 0.64 with hyperemia
(p < 0.001). Receiver-operating characteristics conﬁrmed
that the diagnostic accuracy of iFR was similar to resting Pd/
Pa (pressure distal to the lesion/pressure proximal to the
lesion) and trans-stenotic pressure gradient and was signiﬁ-
cantly inferior to hyperemic iFR. Analysis of a retrospectively
acquired dataset showed similar results. The investigators
concluded that iFR correlates weakly with FFR and is not
independent of hyperemia, and it therefore cannot be rec-
ommended for clinical decision making in patients with
CAD (13).
A second study involving 1,129 patients, including 120
with combined pressure-ﬂow data, evaluated pressure-only
and combined pressure-ﬂow clinical data from several cen-
ters empirically, by using pressure-ﬂow physiology and
1,000 Monte Carlo simulations (14). The clinical data
showed that iFR was þ0.09 higher than FFR on average,
with 0.17 limits of agreement. Diastolic resting resistance
was 2.5 times higher than mean hyperemic resistance in
patients. Classic pressure-ﬂow physiology explained clinical
observations well, with a coefﬁcient of determination of
>0.9. The investigators concluded that iFR provides both a
biased estimate of FFR, on average, and an uncertain esti-
mate of FFR in individual cases (14). An editorial by Samady
and Gogas (15) nicely summarized this ongoing debate.
The FIRST (Fractional Flow Reserve and Intravascular
Ultrasound Relationship Study) compared these 2 ap-
proaches in a multicenter, prospective, international registry
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572of 350 patients (367 lesions) with intermediate coronary
lesions (40% to 80% stenosis by angiography). A minimum
lumen area <3.07 mm2 by intravascular ultrasonography
(64.0% sensitivity, 64.9% speciﬁcity, area under curve¼ 0.65)
was the best threshold value for identifying FFR <0.8. The
accuracy improved when reference vessel diameter–speciﬁc
analyses were performed (16).
Anti-Xa therapy and PCI. The ATLAS ACS-2–TIMI 51
(Anti-Xa Therapy to Lower Cardiovascular Events in
Addition to Standard Therapy in Subjects With Acute
Coronary Syndrome–Thrombolysis In Myocardial Infarction
51) trial studied 7,817 patients presenting with an ST-
segment elevation myocardial infarction (STEMI) who
were randomly assigned to twice daily rivaroxaban 2.5 mg,
rivaroxaban 5 mg, or placebo (17). Rivaroxaban reduced the
primary efﬁcacy endpoint of cardiovascular death, MI, or
stroke, compared with placebo (8.4% vs. 10.6%, HR: 0.81,
for intention to treat; and 8.3% vs. 9.7%, HR for modiﬁed
intention to treat (HR: 0.85, 95%CI: 0.70 to 1.03, p¼ 0.09).
This reduction emerged by 30 days and was evident in ana-
lyses that included events while patients received background
dual antiplatelet therapies. Rivaroxaban versus placebo
increased non-coronary artery bypass graft surgery (CABG)
major bleeding (2.2% vs. 0.6%; p < 0.001) and intracranial
hemorrhage (0.6% vs. 0.1%; p ¼ 0.015) without a signiﬁcant
increase in fatal bleeding (17). In a second ATLAS-ACS 2–
TIMI 51 substudy, among acute coronary syndrome patients
who had a stent placed before or at the time of the index
event, rivaroxaban signiﬁcantly reduced deﬁnite and probable
stent thrombosis in the pooled and the 2.5 mg twice-daily
treatment groups when compared with placebo, with a
trend toward a reduction in the 5 mg twice-daily treatment
group. Among patients who received both aspirin and a
thienopyridine, the beneﬁt of rivaroxaban emerged during the
period of active treatment with dual antiplatelet therapy (HR:
0.68, combined rivaroxaban group vs. placebo). Among
stented patients who were treated with dual antiplatelet
therapy, there was a mortality reduction among those treated
with twice-daily rivaroxaban 2.5 mg (HR: 0.56) (18).
Antiplatelet therapy. The PRECLOP (High On-
Treatment Platelet Reactivity Following Peripheral Endo-
vascular Procedures) trial prospectively assessed the optimal
cut-off value of high platelet reactivity (HPR) with the Ver-
ifyNow P2Y12 point-of-care test (Accumetrics, San Diego,
California) in 100 consecutive patients receiving clopidogrel
for peripheral endovascular procedures (19). According to
receiver-operating characteristic curve analysis, the optimal
cut-off value for the composite endpoint was P2Y12 reaction
units (PRU) 234 (area under the curve 0.883, sensitivity
92.1%, speciﬁcity 84.2%). Cox multivariate regression anal-
ysis identiﬁed HPR (PRU 234) as the only independent
predictor of an increased number of adverse events.
TheWorkingGroup onOn-Treatment Platelet Reactivity
provided an update on the role of proposed cut-off values for
HPR to adenosine diphosphate and summarized the accu-
mulating data of HPR as a prognostic risk factor (20). Theypoint out that recent prospective randomized trials of platelet
function testing did not demonstrate clinical beneﬁt, thus
questioning whether treatment modiﬁcation based on the
results of current platelet function testing platforms can
actually inﬂuence outcomes. However, they also point out
potential limitations associated with these randomized trials.
In view of recent data showing that low on-treatment platelet
reactivity to adenosine diphosphate is associated with a higher
risk of bleeding, a therapeutic window may exist for P2Y12
inhibitor therapy. They discuss cut-off values for high and
low platelet reactivity that might be used in future in-
vestigations of personalized antiplatelet therapy (20).
In patients with STEMI (n ¼ 50) undergoing primary
PCI and being treated with bivalirudin, prasugrel (60 mg
load) was noninferior to ticagrelor (180 mg load) in terms of
residual platelet reactivity measured with the VerifyNow
assay 2 h after receiving the loading dose (21). High residual
platelet reactivity (PRU 240) was found in 44% and 60%
of the prasugrel- and ticagrelor-treated patients, respectively.
Independent predictors of high residual platelet reactivity at
2 h were morphine use (OR: 5.29; p ¼ 0.012) and baseline
PRU value (OR: 1.014; p ¼ 0.046).
In aspirin-treated stable CAD patients (n ¼ 155), prasu-
grel 5 mg in the very elderly (age 75 years; n ¼ 73) atten-
uated platelet inhibition and met pre-speciﬁed noninferiority
criterion versus prasugrel 10 mg in nonelderly persons (n ¼
82), with signiﬁcantly better pharmacodynamic response and
fewer nonresponders compared with clopidogrel 75 mg in the
very elderly (22). In another study of aspirin-treated stable
CAD patients, 56 nonsmokers and 54 smokers were
randomly allocated to clopidogrel 75 mg daily or prasugrel 10
mg daily for 10 days and crossed over after a 14-day washout
(23). During clopidogrel therapy, inhibition of platelet ag-
gregation was lower and PRU and the vasodilator-stimulated
phosphoprotein phosphorylation (VASP) platelet reactivity
index were higher in nonsmokers than in smokers (p¼ 0.043,
p ¼ 0.005, and p ¼ 0.042, respectively). Greater antiplatelet
effects were present after prasugrel treatment regardless of
smoking status (p < 0.001 for all comparisons). That might
be a potential mechanism for the smokers’ paradox observed
with clopidogrel therapy.
Currently approved P2Y12 antagonists are all oral drugs
and absorption from the gastrointestinal track may be
affected by comorbid conditions such as cardiogenic shock,
the delivery of hypothermia (24) as well as by co-adminis-
tration of drugs that may affect gastrointestinal motility and
absorption. This is particularly important in the setting of
primary PCI for STEMI as the procedure needs to be done
before full effect of P2Y12 inhibitors is manifest. Hobl et al.
(25) considered this challenge and its relation to morphine,
which is often given to patients with STEMI. They ran-
domized 24 healthy volunteers to 5 mg morphine intrave-
nously vs. placebo after receiving a loading dose of 600 mg of
clopidogrel, in a cross-over design. The co-administration of
morphine decreased clopidogrel absorption (p ¼ 0.025), the
area under the curve for the metabolites of clopidogrel by
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57352% (p ¼ 0.001) and delayed the maximal inhibition of
platelet aggregation on average by 2 h (n ¼ 24; p > 0.001).
While performed in normal volunteers, these ﬁndings have
important implications for the treatment of STEMI pa-
tients. If and when intravenous P2Y12 inhibitors such as
cangelor become available, they will help address this
important issue.
Coronary and peripheral stent trials. A meta-analysis of
22 trials including 12,453 randomized patients comparing
drug-eluting stents (DES) versus bare-metal stents (BMS)
was performed. At 1-year follow-up, cobalt-chromium
everolimus-eluting stents (CoCr-EES) were associated with
signiﬁcantly lower rates of cardiac death or MI and stent
thrombosis than BMS. Differences in stent thrombosis were
apparent as early as 30 days and were maintained for 2 years.
The CoCr-EES were also associated with signiﬁcantly lower
rates of 1-year stent thrombosis compared with paclitaxel-
eluting stents. Sirolimus-eluting stents were also associated
with signiﬁcantly lower rates of 1-year cardiac death/MI
than BMS. The CoCr-EES, paclitaxel-eluting stents, and
sirolimus-eluting stents, but not zotarolimus-eluting stents
(ZES), had signiﬁcantly lower rates of 1-year target vessel
revascularization (TVR) than BMS, with sirolimus-eluting
stents also showing lower rates of TVR than paclitaxel-
eluting stents (26).
The EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting) and the
RESOLUTE Korea registries prospectively enrolled 3,056
patients treated with the EES and 1,998 patients treated
with ZES, respectively, without exclusions (27). Off-label
indications existed in 2,217 patients treated with EES and
1,613 treated with ZES. The stent- and patient-related
outcomes did not differ between EES and ZES at 1 year,
which was corroborated by similar results from the pro-
pensity score–matched cohort. The rate of deﬁnite or
probable stent thrombosis (18 [0.6%] vs. 7 [0.4%]; p ¼
0.306) also was similar. In multivariate analysis, off-label
indication was the strongest predictor of target lesion failure.
In the DKCRUSH-III (Double Kissing [DK] Crush
Versus Culotte Stenting for the Treatment of Unprotected
Distal Left Main Bifurcation Lesions) trial, a multicenter
randomized study comparing double-stent techniques,
a total of 419 patients with unprotected left main coronary
artery bifurcation lesions were randomly assigned to DK
crush (n ¼ 210) or Culotte stenting (n ¼ 209) for distal
bifurcation lesions (28). Patients in the Culotte group had
a signiﬁcantly higher 1-year major adverse cardiac event rate
(16.3%), mainly driven by increased TVR (11.0%),
compared with the DK group (6.2% and 4.3%, respectively;
all p < 0.05). In-stent restenosis (ISR) rate in the side
branch (SB) was 12.6% in the Culotte group and 6.8% in
the DK group (p ¼ 0.037). Deﬁnite stent thrombosis rate
was 1.0% in the Culotte group and 0% in the DK group
(p ¼ 0.248). Among patients with bifurcation angle 70,
NERS (New Risk Stratiﬁcation) score 20, and SYNTAX
(Synergy Between Percutaneous Coronary InterventionWith TAXUS and Cardiac Surgery) score 23, the 1-year
major adverse cardiac event rates in the DK group (3.8%,
9.2%, and 7.1%, respectively) were signiﬁcantly different
from those in the Culotte group (16.5%, 20.4%, and 18.9%,
respectively; all p < 0.05) (28). These data favor the DK
approach.
In a second study, patients with symptomatic CAD
undergoing PCI for unprotected left main coronary artery
lesions were randomly assigned to receive either ZES
(n ¼ 324) or EES (n ¼ 326) (29). At 1 year, the cumulative
incidence of the primary endpoint was 17.5% in the ZES
group and 14.3% in the EES group (relative risk: 1.26; p ¼
0.25). Three patients in the ZES group (0.9%) and 2 pa-
tients in the EES group (0.6%) experienced deﬁnite/prob-
able stent thrombosis (p > 0.99). All-cause mortality at 1
year was equal in the 2 groups. Angiographic restenosis of
21.5% of those with ZES and 16.8% with EES was not
signiﬁcantly different.
The Nordic Bifurcation Study reported the 5-year follow-
up results in 413 patients with a coronary bifurcation lesion
comparing a simple strategy of main vessel stenting with
optional SB stenting or to a complex strategy of stenting of
both main vessel and SB (30). The combined safety and
efﬁcacy endpoint of cardiac death, non–procedure-related
MI, and TVR was seen in 15.8% in the optional SB stenting
group as compared to 21.8% in the main vessel group and
SB stenting group (p ¼ 0.15). All-cause death was seen in
5.9% versus 10.4% (p ¼ 0.16) and non–procedure-related
MI in 4% versus 7.9% (p ¼ 0.09) in the optional SB stenting
group versus the main vessel group and SB stenting group,
respectively. The rates of TVR were 13.4% versus 18.3%
(p ¼ 0.14) and the rates of deﬁnite ST were 3% versus
1.5% (p ¼ 0.31) in the optional SB stenting group versus the
main vessel group and SB stenting group, respectively.
In a prospective, randomized, single-blind, multicenter
study, 141 patients with symptomatic peripheral arterial
disease were assigned to treatment with heparin-bonded,
covered stents (Viabahn, W. L. Gore & Associates, Flag-
staff, Arizona; n ¼ 72) or BMS (n ¼ 69) for long femo-
ropopliteal artery disease (31). The 12-month primary
patency rates in the Viabahn and BMS groups by intention to
treat, which was ﬂawed by major protocol deviations in 8.5%
of the patients, were 70.9% and 55.1% (log-rank test p ¼
0.11); treatment per-protocol was 78.1% and 53.5% (HR:
2.23; log-rank test p ¼ 0.009). In lesions 20 cm (Trans-
Atlantic Inter-Society Consensus Class D), the 12-month
patency rate was signiﬁcantly longer in Viabahn patients in
both the intention to treat and the treatment per-protocol
analyses. Freedom from target lesion revascularization
(TLR) was 84.6% for Viabahn versus 77.0% for BMS (95%;
p ¼ 0.37). The ankle-brachial index in the Viabahn group
signiﬁcantly increased to 0.94 compared with the BMS
group (0.85) at 12 months; the difference was not signiﬁcant.
The role of colchicine 0.5 mg orally twice daily or placebo
for 6 months was studied in 196 patients receiving coronary
BMS (32). The angiographic ISR rate was 16% in the
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574colchicine group and 33% in the control group (odds ratio
[OR]: 0.38; p ¼ 0.007). The number needed to treat to
avoid 1 case of angiographic ISR was 6 (95% CI: 3.4
to 18.7). The results were similar for intravascular ultraso-
nography–deﬁned ISR. Lumen area loss was 1.6 mm2
in colchicine-treated patients and 2.9 mm2 in the control
group (p ¼ 0.002). Treatment-related adverse events were
largely limited to gastrointestinal symptoms.
Complete revascularization. A systematic review and
meta-analysis of studies comparing complete revasculariza-
tion (CR) versus incomplete revascularization (IR) in pa-
tients with multivessel CAD identiﬁed 35 studies involving
89,883 patients, of whom 45,417 (50.5%) received CR
and 44,466 (49.5%) received IR from 1970 through
September 2012 (33). IR was more common after PCI than
after CABG (56% vs. 25%; p < 0.001). Relative to IR, CR
was associated with lower long-term mortality (risk ratio
[RR]: 0.71; p < 0.001), MI (RR: 0.78; p < 0.001), and
repeat coronary revascularization (RR: 0.74; p < 0.001). The
mortality beneﬁt associated with CR was consistent across
studies irrespective of revascularization modality and deﬁ-
nition of CR (anatomic vs. nonanatomic). The researchers
concluded that CR is achieved more commonly with CABG
than with PCI, and may be the optimal revascularization
strategy for patients with multivessel CAD.
Natsuaki et al. (34) conducted a randomized controlled
noninferiority trial comparing a biodegradable polymer
biolimus-eluting stent to a durable polymer EES in Japan.
This was a prospective, multicenter, randomized, open-
labeled noninferiority trial that randomized 3,235 patients
to either arm. At 1 year, the primary efﬁcacy endpoint of
TLR was similar in the biolimus and everolimus arms: 4.2%.
Cumulative incidence of deﬁnite stent thrombosis was low
and not statistically signiﬁcant between the stents; an
angiographic substudy demonstrated noninferiority
regarding the endpoint of end-segment late loss. Thus, the
biodegradable polymer stent was noninferior to the durable
polymer EES in this study.
An important paper examines the incidence and outcome
of PCI performed in patients who had not received pre-
procedural aspirin (35). Data were obtained in some
65,000 patients cared for at 44 hospitals in Michigan.
Patients who did not receive aspirin were more likely to
have had prior gastrointestinal bleeding or to present with
cardiogenic shock or after arrest. In propensity matching,
the absence of aspirin before PCI was associated with the
higher rate of death (3.9 vs. 2.8) and stroke (0.5 vs. 0.1),
with no difference in the need of transfusions. These data
clearly demonstrate that lack of aspirin before PCI is
associated with signiﬁcantly increased in-hospital mortality
and stroke.
Percutaneous coronary intervention. Data (n ¼ 144,039)
from the SCAAR (Swedish Coronary Angiography and
Angioplasty Registry) show that from 1990 to 2010, the age
of patients undergoing PCI increased from 60.1  9.9 years
to 67.1  11.2 years, whereas the proportion of patientspresenting with unstable CAD and STEMI increased from
27.4% and 6.2% to 47.7% and 32.5%, respectively (36).
Additionally, a larger proportion of patients undergoing PCI
in the later years had diabetes mellitus and multivessel dis-
ease. The 1-year mortality increased from 2.2% (1990 to
1995) to 5.9% (2009 to 2010), but after adjustment for age
and indication, a modest decrease was shown, mainly among
STEMI patients.
In contemporary PCI (2009 to 2011), Aggarwal et al. (37)
performed a detailed chart review of all deaths within
30 days of PCI at a tertiary care hospital and reported a
30-day mortality of 2%. Of these, 42% were from noncardiac
causes, and death certiﬁcates were only 58% accurate in
appropriately classifying cardiac versus noncardiac death. In
an accompanying editorial, Pinto and Pride (38) suggest that
this study shows that reported PCI mortality as a quality
measure should be reconsidered given that the majority of
deaths after PCI are unrelated to the procedure and that
death certiﬁcates are frequently inaccurate.
Data from a number of small single-center studies support
the safety of same-day discharge for elective PCI patients.
Brayton et al. (39) performed a meta-analysis of 37 studies
(n ¼ 12,803) including 7 randomized clinical trials (RCTs)
(n ¼ 2,738) and 30 observational studies (n ¼ 10,065)
evaluating same-day discharge after PCI. In both cohorts,
PCI was primarily performed for stable angina, and vascular
access was predominantly radial (60%) in the RCTs and
femoral (70%) in the observational studies. In the RCTs, no
difference was seen between same-day discharge and routine
overnight observation with regard to death/MI/TLR (OR:
0.90; p ¼ 0.78) or for major bleeding/vascular complications
(OR: 1.69; p ¼ 0.15). In the observational studies, the pri-
mary outcome of death/MI/TLR occurred at a pooled rate of
1.00%, and major bleeding/vascular complications occurred
at a pooled rate of 0.68%.
Substantial interest has recently been generated for the
treatment of chronic total occlusions with the development of
newer devices and techniques, which has resulted in increased
procedural success for chronic total occlusions. Valenti et al.
(40) reported long-term results of the Florence chronic total
occlusion PCI registry that included all consecutive chronic
total occlusions (>3 months) treated with DES from 2003 to
2010. A total of 1,035 patients underwent chronic total oc-
clusion PCI with a procedural success of 77%. The 6- to 9-
month angiographic follow-up (82%) revealed a reocclusion
rate of 7.5%, whereas the binary restenosis/reocclusion rate
was 20%. Everolimus-eluting stents were associated with a
signiﬁcantly lower reocclusion rate compared with other DES
(3.0% vs. 10.1%; p ¼ 0.001). Subintimal tracking and re-
entry technique was associated with a reocclusion rate of 57%.
By multivariable analysis, the subintimal tracking and re-
entry technique (OR: 29.5; p < 0.001) and everolimus-
eluting stent use (OR: 0.22; p < 0.001) were independently
related to the risk of reocclusion.
Bifurcation lesions can be treated by a number of tech-
niques during PCI. Hahn et al. (41) reported results of the
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registry that enrolled all consecutive coronary bifurcation
lesions treated with DES (SB 2.3 mm) between 2003 and
2009 at 18 centers in South Korea. SB occlusion occurred in
8.7% (n ¼ 187) of 2,227 bifurcation lesions treated. In
multivariate analysis, independent predictors of SB occlusion
were pre-procedural SB stenosis 50% (OR: 2.34; 95% CI:
1.59 to 3.43; p < 0.001), proximal main vessel
stenosis 50% (OR: 2.34; 95% CI: 1.57 to 3.50; p < 0.001),
SB lesion length (OR: 1.03; 95% CI: 1.003 to 1.06;
p ¼ 0.03), and presenting with an acute coronary syndrome
(OR: 1.53; 95% CI: 1.06 to 2.19; p ¼ 0.02). Of the 187
occluded SBs, ﬂow was restored spontaneously in 13% and
by SB intervention in 55%. Jailed wire in the SB was asso-
ciated with ﬂow recovery (74% vs. 57%; p ¼ 0.02) and
cardiac death/MI occurred more frequently among patients
with SB occlusion (adjusted HR: 2.34; p ¼ 0.02).
Robotically-assisted PCI has the potential to reduce ra-
diation exposure to the interventional cardiologist and
improve procedural efﬁciency. Feasibility of this approach
using the CorPath 200 robotic system (Corindus Vascular
Robotics, Natick, Massachusetts) was demonstrated in the
PRECISE (Percutaneous Robotically-Enhanced Coronary
Intervention) study, a single arm multicenter registry that
enrolled 164 subjects (42). Robotically-assisted PCI without
manual conversion was achieved in 98.8% of subjects
without any complications. Clinical procedural success was
achieved in 97.6%, with 4 subjects (2.4%) having a peri-
procedural non–Q-wave MI. Radiation exposure to the
primary operator was 95.2% lower than the levels found at
the traditional table position.
Bleeding. Sarafoff et al. (43) analyzed a consecutive series
of 377 patients who underwent DES placement (between
2009 and 2011) and had a clinical indication for oral anti-
coagulation therapy in addition to dual antiplatelet therapy
for at least 6 months. Signiﬁcantly higher TIMI (Throm-
bolysis In Myocardial Infarction) major/minor bleeding rates
were observed with prasugrel-treated patients (n ¼ 21)
versus clopidogrel-treated patients (n ¼ 356 [28% vs.
6.7%; unadjusted HR: 4.6, p < 0.001; adjusted HR: 3.2,
p ¼ 0.03]). No signiﬁcant difference in the combined
ischemic secondary endpoint was observed. Although these
are nonrandomized data, an accompanying editorial by
Gurbel and Tantry (44) also reiterated that considerably
more work is required for better understanding bleeding and
ischemic risk with triple therapy, and caution should be
exercised in using potent P2Y12 inhibitors like prasugrel
with oral anticoagulants.
Data from the National Cardiovascular Data Registry
(NCDR) CathPCI Registry (n ¼ 294,769) shows that the
use of transradial primary PCI for STEMI increased from
0.9% to 6.4% (p < 0.0001) from 2007 to 2011 in the United
States (45). Transradial PCI was associated with longer
median door-to-balloon time (78 min vs. 74 min; p <
0.0001) and similar procedural success. However, transradial
access was associated with lower adjusted risk of bleeding(OR: 0.62; p < 0.0001) and of in-hospital mortality (OR:
0.76; p ¼ 0.04).
In another study from the NCDR CathPCI Registry
(n ¼ 570,777), from July 1, 2009, to March 31, 2011, the
use of bleeding avoidance strategies (vascular closure devices,
bivalirudin, radial approach) between women (32.5%) and
men (67.5%) were compared and differed only very slightly
(75.4% vs. 75.7%; p ¼ 0.01) (46). However, when a bleeding
avoidance strategy was not used, women had signiﬁcantly
higher rates of bleeding than men (12% vs. 6%; p < 0.01).
Both sexes had similar adjusted risk reductions of bleeding
when any bleeding avoidance strategy was used (women,
OR: 0.60; men, OR: 0.62). Women and men had lower
absolute bleeding risks with the use of bleeding avoidance
strategies, but absolute risk differences were greater in
women (6% vs. 3%; p < 0.01).
Data from the 24-center TRIUMPH (Translational
Research Investigating Underlying Disparities in Acute
Myocardial Infarction Patients’Health Status) study of 3,560
patients revealed that the prevalence of nuisance bleeding
(Bleeding Academic Research Consortium type I) was
37% over 12 months after an acute MI (47). After adjust-
ment for baseline bleeding and mortality risk, ongoing dual
antiplatelet therapy was the strongest predictor of nuisance
bleeding (RRs: 1.44 at 1 month, 1.89 to 2.65 at 6 months,
and 1.39 at 12 months; p < 0.01 for all comparisons).
Nuisance bleeding at 1 month was independently associated
with a decrement in quality of life at 1 month (2.81 points
on the EuroQOL 5-dimension visual analog scale; 95% CI:
1.09 to 5.64) and nonsigniﬁcantly toward higher rehospi-
talization (HR: 1.20, 95% CI: 0.95 to 1.52).
Structural heart disease. The feasibility of 2 new tech-
niques for closure of the left atrial appendage in patients
with nonvalvular atrial ﬁbrillation and contraindication
for warfarin was reported. Urena et al. (48) percutaneously
excluded the left atrial appendage in 52 patients at 7 Ca-
nadian centers using the Amplatzer (St. Jude Medical,
Minneapolis, Minnesota) cardiac plug. Procedural success
was 98%, mild peridevice leak was observed in 16% of cases
by transesophageal echocardiography (TEE) at 6-month
follow-up, and the rates of death, stroke, and systemic em-
bolism at 20  5 months of follow-up were 5.8%, 1.9%, and
0%, respectively. Using a minimally invasive surgical tech-
nique in 30 patients with a history of thromboembolism,
Ohtsuka et al. (49) thoracoscopically removed the left atrial
appendage without complications, and at 16  9.7 months
of follow-up, no recurrent thromboembolic events were
reported.
Maisano et al. (50) reported the initial post-approval re-
sults of treating patients with severe mitral regurgitation
with the MitraClip (Abbott Vascular, Santa Clara, Cali-
fornia). In 567 patients with signiﬁcant mitral regurgitation
(97% with 3 to 4þ) treated at 14 European sites, the implant
success rate was 99%, with 30-day and 1-year mortality
rates of 3.4% and 18.2%, respectively. Single leaﬂet device
attachment was reported in 27 patients (4.8%) but there
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required mitral valve surgery within 12 months after the
MitraClip implant procedure. There was signiﬁcant reduc-
tion in the severity of mitral regurgitation at 1-year follow-
up compared with baseline (p < 0.0001), with 78.9% of
patients free from mitral regurgitation >2þ. At 12-month
follow-up, 71.4% of patients had New York Heart Associ-
ation (NYHA) functional class I or II functional status.
These data support the beneﬁt of the MitraClip in practice.
Peripheral vascular disease. In a survey involving >3.6
million U.S. adults over the age of 40 years, Sanji et al. (51)
reported that the prevalence of peripheral arterial disease
(PAD), namely, ankle-brachial index (ABI) <0.9, carotid
artery stenosis >50%, and abdominal aortic aneurysm
>3 cm, was 3.7%, 3.9%, and 0.9%, respectively. Prevalence
of disease in each vascular territory increased with age and
after multivariable adjustment; the odds of PAD (OR: 2.14),
carotid artery stenosis (OR: 1.80), and abdominal aortic
aneurysm (OR: 2.33) increased with each decade of life.
Lu et al. (52) presented their successful experience of
treating ascending aortic arch dissections with endovascular
stent grafts (n ¼ 15; acute ¼ 5, chronic ¼ 10) in patients
who were not surgical candidates. Procedural success was
100%, and at a median follow-up of 26 months, there was
no mortality and only 1 patient required additional endo-
vascular treatment for a new dissection.
In a small study (n ¼ 61), Huang et al. (53) obtained
baseline cerebral perfusion and performed neurocognitive
testing before carotid artery stenting in subjects with either
carotid artery occlusion (n ¼ 22) or high-grade stenosis
(n ¼ 39). In subjects with objective baseline abnormal ce-
rebral perfusion, successful carotid stenting was associated
with marginal improvement in neurocognitive function.
Two-year outcomes from the Zilver (Cook Medical,
Bloomington, Indiana) paclitaxel-eluting (PTX) stent ran-
domized controlled trial (n ¼ 474) demonstrated superiority
for the Zilver PTX stent (primary patency 74% vs. 26%
percutaneous transluminal angioplasty; p < 0.01) for the
treatment of femoropopliteal disease (54). The provisional
stent group in the failed percutaneous transluminal angio-
plasty arm also beneﬁted with placement of a Zilver PTX
stent (primary patency 83% vs. 64% BMS; p < 0.01). Two-
year freedom from TLR with primary DES placement was
86.6% in the randomized controlled trial and 80.5% in a
single-arm registry (n ¼ 787), which was also reported in the
same paper.
Optimal management of carotid artery disease before
open heart surgery (OHS) remains a controversial subject.
Over a 12-year period (1997 to 2009), Shishehbor et al. (55)
retrospectively compared and reported early and late out-
comes with 3 different carotid revascularization approaches
before OHS (n ¼ 350). Using all-cause mortality, stroke,
and MI as a combined primary endpoint, after propensity-
adjusted analysis, staged carotid artery stenting (CAS)-
OHS (n ¼ 110) had similar outcomes as combined carotid
endarterectomy (CEA)-OHS (n ¼ 195; adjusted HR: 0.99;p ¼ 0.97) and superior outcomes to staged CEA-OHS (n ¼
45; adjusted HR: 0.49; p ¼ 0.06) at the early (1-year) hazard
phase. Subsequently, staged CAS-OHS patients experi-
enced signiﬁcantly fewer late hazard phase events compared
with both staged CEA-OHS (adjusted HR: 0.33; p ¼ 0.01)
and combined CEA-OHS (adjusted HR: 0.35; p ¼ 0.003).
In an accompanying editorial, Mahmud and Reeves (56)
pointed out that the study provided clarity in the manage-
ment of patients with carotid disease requiring OHS, and
the systematic collection of all intertreatment events for the
staged revascularization procedures was a particular strength
of the study.
Utilization of high-dose statin therapy and antiplatelet
therapy before carotid artery stenting has not been extensively
investigated. In the ARMYDA-9 CAROTID (Clopidogrel
and Atorvastatin Treatment During Carotid Artery Stent-
ing) study, 156 patients undergoing carotid stenting were
randomized using a 2  2 factorial design to either a 600 mg
(n ¼ 78) or 300 mg (n ¼ 78) clopidogrel load given 6 h
before intervention, and either an atorvastatin reload (n¼ 76;
80 mg þ 40 mg initiated 12 h before the procedure) or no
statin reload (n¼ 80) (57). The 30-day incidence of transient
ischemic event/stroke or new ischemic lesions on cerebral
diffusion-weighted magnetic resonance imaging (MRI)
performed at 24 to 48 h (primary endpoint) was lower in the
600 mg clopidogrel load arm (18% vs. 35% in the 300 mg
load arm; p ¼ 0.019) and in the atorvastatin reload arm
(18% vs. 35% in the no statin reload arm; p ¼ 0.031). High-
dose clopidogrel also reduced the transient ischemic event/
stroke rate at 30 days (0% vs. 9%; p ¼ 0.02, secondary
endpoint) without an increase in bleeding.
Coronary artery disease. An interesting question through
the ages has been whether the presence and severity of
symptoms of angina pectoris is related to the risk of all-cause
mortality in cardiovascular events. Dagenais et al. (58) per-
formed a post-hoc analysis of 2,364 patients with type
2 diabetes mellitus and documented CAD from the BARI
2D (Bypass Angioplasty Revascularization Investigation
2 Diabetes) trial for the occurrence of death, MI, or stroke
over 5 years (58). They found that the cumulative death rates
were 12%, 14%, and 10% for patients with angina, angina
equivalent, and no angina, respectively. Similar nonsigniﬁ-
cant ﬁndings were observed for composite event rates. Thus,
type 2 diabetes patients with stable CAD were at similar risk
of cardiovascular events with or without angina, suggesting
that these patients may be similarly managed for risk strati-
ﬁcation and preventive therapies. In an accompanying
editorial, Stone (59) questioned whether, on the basis of these
ﬁndings, we should aggressively screen all patients with
diabetes to determine if coronary disease and ischemia are
present regardless of symptoms. He concluded, however, that
for the present, the minimum should be very aggressive
optimization of risk factor management for all diabetic
patients.
Well-conducted clinical trials have yielded conﬂicting
data regarding the value of angiotensin-converting enzyme
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(ARBs) for reducing cardiovascular events in patients
without heart failure (HF). Therefore, Savarese et al. (60)
conducted a meta-analysis to assess the effects of ACEI
and ARB therapy on the composite outcome of cardiovas-
cular death, MI, and stroke as well as all-cause death, new-
onset HF, and new-onset diabetes in high-risk patients
without HF. They examined 26 randomized trials involving
108,212 patients without HF. They found that ACEI and
ARB reduced the risk of a composite outcome of cardio-
vascular death, MI, and stroke, and that ACEI also reduced
the risk of all-cause death, new-onset HF and new-onset
diabetes. They concluded that ACEI were the agents of
choice but ARB could be applied with patients for whom
ACEI could not be administered.
The role of ranolazine in patients with type 2 diabetes
mellitus and chronic stable angina was examined in the
TERISA (Type 2 Diabetes Evaluation of Ranolazine in
Subjects With Chronic Stable Angina) trial (61). The
rationale for this study was based not only on the high burden
of angina in diabetic patients with CAD, but also the
demonstrated improvement of glycemic control provided by
ranolazine. The investigators found a small but signiﬁcant
reduction in weekly angina frequency (3.8 vs. 4.3) in controls,
as well as a reduction in sublingual nitroglycerin (1.7 vs. 2.1)
with ranolazine versus placebo. Thus, this study indicated a
small but signiﬁcant beneﬁt of ranolazine for patients with
diabetes. In an accompanying editorial, Lew and DeMaria
(62) observed that this was a relatively short-term study with
the somewhat subjective endpoint of angina and a small
beneﬁt. Nevertheless, it raised the intriguing question of the
role of glycemic control in producing the beneﬁt.
Because the left anterior descending coronary artery
(LAD) most commonly perfuses the right bundle branch
and left anterior fascicle, Strauss et al. (63) hypothesized that
the proximal LAD occlusion should cause right bundle
branch block and not left bundle branch block. To assess this
hypothesis, they performed electrocardiography (ECG) and
MRI for scar quantiﬁcation in 233 patients with left ven-
tricular (LV) ejection fraction <35%, comparing patients
with right bundle branch block to patients with left bundle
branch block in nonspeciﬁc conduction delay. They found
that despite equivalent ejection fractions, patients with right
bundle branch block had larger infarct scar size than left
bundle branch block patients (24% vs. 6%; p < 0.0001).
They concluded that LAD occlusion most often caused
right bundle branch block, whereas left bundle branch block
was most commonly caused by nonischemic pathologies. In
an accompanying editorial, Engel and Wolf (64) pointed out
that the widely held suspicion that left bundle branch block
represented LAD occlusion was erroneous, and that this
study had conﬁrmed pathology ﬁndings indicating that oc-
clusion of the LAD was most likely to result in right bundle
branch block.
A provocative publication in the Journal was an expert
consensus document dealing with the consideration of a newdeﬁnition of clinically relevant MI after coronary revascu-
larization. In this document, Moussa et al. (65) on behalf of
the Society for Cardiovascular Angiography and In-
terventions, pointed out that the deﬁnition for post-
procedural (post-PCI, post-CABG) MI was based on
troponin, but that the prognostic signiﬁcance of troponin in
elevations was much less validated for events than creatine
kinase-myocardial band (CK-MB). They, therefore, pro-
posed that the diagnosis of MI after coronary revasculari-
zation be based on CK-MB because it was clinically relevant
for prognosis and recommended. In an accompanying
editorial, White (66) pointed out that whether post-
procedural myonecrosis is a marker of atherosclerotic
burden and PCI complexity or a direct risk factor is unre-
solved. Therefore, new deﬁnitions of periprocedural MI will
of necessity be arbitrary. He maintained that the rationale for
the universal deﬁnition of MI was well established, and that
if CK-MB were utilized to recognize post-procedural MI,
values for troponin should be provided as well.
Although the value of internal thoracic artery (ITA)
grafting to the LAD prolongs survival and reduces events in
coronary patients, it is uncertain whether a left internal
thoracic artery (LITA) graft is of value in patients who have
undergone previous CABG with either LITA or saphenous
vein. Therefore, Sabik et al. (67) examined the value of
LITA grafts in a group of 3,473 patients undergoing
reoperation for coronary disease at the Cleveland Clinic.
They determined that the unadjusted hospital mortality was
lower with LITA than with saphenous vein bypass (3.1% vs.
5.6%; p < 0.008) in propensity-matched groups. In addi-
tion, at 20 years LITA grafting of the LAD at reoperation
resulted in an absolute mortality risk reduction of 6.0%.
Based on these ﬁndings, these investigators recommended
that LITA should be the graft of choice in revascularizing
the LAD at coronary reoperation. In an accompanying
editorial, Jones (68) indicated that propensity matching was
a limited methodology in terms of eliminating all potential
confounding variables. He, therefore, urged caution in
applying the data obtained in this retrospective study to the
application of LITA versus saphenous vein grafts.
Heart valve disease. In view of the emerging data of the
paradoxical effect of obesity upon cardiovascular prognosis,
Rogge et al. (69) analyzed the effect of overweight and
obesity on cardiovascular events in patients with asymp-
tomatic aortic stenosis. Of the 1,664 patients in the SEAS
(Simvastatin Ezetimibe in Aortic Stenosis) substudy, over-
weight and obese patients had a higher prevalence of hy-
pertension, abnormal LV ventricular geometry, and lower
midwall shortening. The AS progression rate did not differ
between classes based on body mass index, and being
overweight had no signiﬁcant inﬂuence on the rate of
ischemic cardiovascular or aortic stenosis-related events,
although overweight and obesity had a higher rate of total
mortality and combined hospital stay for HF and death from
any cause. In an accompanying editorial, Dumesnil and
Pibarot (70) cautioned that the obesity paradox reported in
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that AS patients should continue to be encouraged to lose
weight.
Controversy continues in regard to the prevalence and
importance of so-called low-gradient severe AS in the
presence of a preserved ejection fraction. Therefore, Lauten
et al. (71) compared echocardiographic and invasive hemo-
dynamic data in 58 patients in whom evidence of this
condition existed. They found that aortic oriﬁce area by
echocardiography and catheterization showed modest
agreement and that systolic gradients were very similar. This
study provided evidence that low-gradient severe AS despite
preserved ejection fraction exists as a real entity independent
of echocardiographic ﬁndings.
In an important study, Beach et al. (72) assessed the in-
ﬂuence of CAD on the outcome of patients with severe AS
undergoing aortic valve replacement. Not surprisingly, pa-
tients with AS and coronary disease were older, more
symptomatic, more likely to be hypertensive, and more likely
to have lower ejection fractions and greater atherosclerotic
burden. They observed that patients with isolated AS and
few comorbidities had the best outcomes; patients with
CAD without myocardial damage had intermediate out-
comes equivalent to propensity-matched isolated AS pa-
tients; and those with coronary disease, myocardial damage,
and advanced comorbidities had the worse outcomes. They
concluded that patients with severe AS and CAD
risk factors should undergo early diagnostic evaluation
and combined aortic valve replacement in CABG before
ischemic myocardial damage occurs. In an accompanying
editorial, Pape and Joffe (73) point out that this study
documents the role of coronary risk factors and comorbid-
ities in determining the long-term prognosis of patients with
AS. They further opine that although these data argue for
more aggressive early evaluation of coronary disease in AS
patients, particularly those with comorbidities, only a ran-
domized prospective trial can prove the value of this
approach.
Given the recent demonstration of the efﬁcacy of TAVR,
Osnabrugge et al. (74) conducted a study to assess the
prevalence of AS in patients over the age of 75 years. In
reviewing 7 studies, they found that the prevalence of severe
AS was approximately 3.4%, and that 75% of such patients
were symptomatic. Because approximately 40% of symp-
tomatic patients did not undergo revascularization, assuming
such patients would ultimately undergo transcathether aortic
valve implantation (TAVI), these investigators concluded
that there may be as many as 300,000 elderly patients who
are TAVI candidates in Europe and the United States. In an
accompanying editorial, Vahanian et al. (75) commented
that some symptomatic AS patients just are not candidates
even for TAVI, but that the magnitude of AS in elderly
patients has a number of regulatory and economic implica-
tions for public health.
The issue of how best to assess aortic annular size in
patients undergoing TAVR was the subject of a number ofstudies comparing echocardiography with computed to-
mography (CT). Thus, studies both by Binder et al. (76) and
Jilaihawi et al. (77) showed that CT of the aortic annulus
reduced paravalvular aortic regurgitation compared with
echocardiography, and recommend that this should be the
imaging modality of choice for assessment of aortic annulus.
To compare the long-term effects of TAVR versus sur-
gical aortic valve replacement (SAVR), Hahn et al. (78)
performed echocardiograms up to 2 years after the pro-
cedures in a core laboratory. They demonstrated that
although both techniques produce signiﬁcant reductions in
aortic gradient and increase in oriﬁce area, TAVR patients
had a higher indexed oriﬁce area, lower prosthesis-patient
mismatch, and more aortic regurgitation. In an accompa-
nying editorial, Hoit (79) pointed out that this study was
important not only for the information it provided regarding
the interventional approach for AS, but also for demon-
strating the value of a core laboratory.
The inﬂuence of coronary obstruction in patients under-
going TAVR was studied in a large multicenter registry by
Ribeiro et al. (80). Of 6,688 patients, 44 had symptomatic
coronary obstruction after TAVR. Although symptomatic
coronary obstruction after TAVR was rare, it was a life-
threatening complication occurring more commonly
among women with balloon-expandable valves and among
patients with previous surgical biothesis. Despite successful
treatment, acute late mortality remained high, indicating the
importance of prevention.
Given the efﬁcacy of TAVR for AS, it was just a matter
of time until this therapy was applied to aortic valve regur-
gitation. Therefore, Roy et al. (81) reported a total of 43
patients who underwent TAVR with the CoreValve pros-
thesis at 14 centers. Eight patients required a second valve
during the index procedure. Post-procedure aortic regurgi-
tation grade 1 was ultimately present in 79% of patients,
and at 12 months the all-cause mortality rate was 1%. These
data suggest that for patients with severe native aortic valve
regurgitation who are deemed to be too high risk
for conventional surgery, TAVR may provide a potential
alternative therapy.
The emergence of TAVR as a therapeutic alternative
for AS has re-emphasized the importance of a heart team
approach to cardiovascular care. In an important state-of-
the-art paper, Holmes et al. (82) provide a strong rationale
for a comprehensive heart team in selecting and imple-
menting the optimal treatment for patients with all forms
of cardiovascular disease, but particularly AS.
Few data exist regarding the natural history of combined
AS and regurgitation. Thus, Zilberszac et al. (83) analyzed
a large database and found that aortic velocity was increased
by both stenosis and regurgitation and that a peak velocity
>4.0 m/s was of value in predicting subsequent events. In an
accompanying editorial, Byrd and Baker (84) point out that,
given the lack of data regarding the natural history of com-
bined AS and regurgitation, the demonstration that simple
aortic valve velocity has important prognostic implications is
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Of greater importance, they indicate that the combination of
valvular lesions tends to progress rapidly, even in patients
who have initially low velocity.
The Journal published 4-year data regarding percutaneous
mitral valve repair using the MitraClip procedure from
the EVEREST II (Endovascular Valve Edge-to-Edge
Repair Study) (85). At 4 years, the rate of the composite
endpoint of freedom from death, surgery, and 3þ to
4þ mitral regurgitation in the intention to treat population
was 39.8% versus 53.4% in the MitraClip and surgical
groups, respectively. Although patients treated with percu-
taneous mitral valve repair more commonly required subse-
quent surgery to treat residual mitral regurgitation after the
ﬁrst year of follow-up, there was no difference in the prev-
alence of moderate to severe mitral regurgitation or mortality
at 4 years.
The success of percutaneous transluminal renal denerva-
tion as treatment for patients with resistant hypertension
stimulated an evaluation of pulmonary artery denervation
for severe pulmonary arterial hypertension. Thus, Chen
et al. (86) reported the ﬁrst preliminary data in 13 patients
in whom pulmonary artery denervation was applied for
pulmonary artery hypertension. Using a specially dedicated
catheter, they reported a signiﬁcant reduction of mean pul-
monary arterial pressure and an improvement of the 6-min
walk distance as well as of the Tei index.
In an accompanying editorial, Galie and Manes (87)
cautioned that these results were very preliminary, were
obtained from a somewhat unusual population, and had
an uncertain pathophysiological basis. They urged that
considerable care should be involved in evaluating this
procedure in the future.
Cardiac metabolic risk. Although bupropion increases the
quit rate of smoking in healthy persons or patients with
stable cardiovascular disease, its role in patients with acute
MI in whom it is started in the hospital is uncertain.
Therefore, Eisenberg et al. (88) conducted a randomized,
prospective, placebo-controlled trial in patients followed up
for 12 months. They observed that two-thirds of the patients
returned to smoking by 12 months after their acute MI, and
that no difference existed between the bupropion group and
control group. In an accompanying editorial, Benowitz and
Prochaska (89) suggested that the Eisenberg study was likely
underpowered, and that a larger sample may have yielded
statistically signiﬁcant results. Nevertheless, based on the
totality of available data, they concluded that there is limited
evidence to support the routine prescription of bupropion or
varenicline for smoking cessation for hospitalized smokers.
An important study addressed the frequency with which
risk factor control is achieved in diabetic patients with CAD.
Farkouh et al. (90) analyzed the data from 3 clinical trials to
assess the efﬁcacy of achieving guideline-driven treatment
goals. They observed that only 18% of diabetic patients in
the COURAGE (Clinical Outcomes Utilizing Revascular-
ization and Aggressive Drug Evaluation) trial, 23% in theBARI 2D trial, and 8% in the FREEDOM (Future
REvascularization Evaluation in patients with Diabetes
mellitus: Optimal management of Multivessel disease) study
met all 4 pre-speciﬁed treatment targets at 1-year follow-up.
They concluded that in these carefully controlled clinical
trials, the low rate of achieving comprehensive risk factor
reduction in patients with coronary disease and diabetes is a
cause for great concern, and suggests that the results in a
population not enrolled in a clinical trial would be less.
An interesting study looked at the effect of binge drinking
upon vascular function. The study compared binge-drinking
college students studied for 1 to 4 days after their last
consumption and abstaining students, utilizing brachial
artery ﬂow mediated dilation with and without nitroglycerin
and examining resistance arterioles obtained by gluteal
biopsy. Endothelin-1 vasoconstriction was enhanced in the
binge-drinking cohort (91), and brachial artery ﬂow medi-
ated dilation was less in the binge drinkers. In an accom-
panying editorial, Vogel (92) points out that interpretation
of these data are complicated by the observation that the
ﬁndings with nitroglycerin stimulation were similar to those
without, peak shear rate was reduced in binge drinkers, and
that binge drinkers had larger brachial arteries. He further
points out that the difference in blood pressure (BP) after
binge drinking could itself convey a signiﬁcant risk.
Considerable interest has recently been focused on
colchicine for prevention of cardiovascular disease. Niforf
et al. (93) performed a prospective randomized clinical trial
in patients with stable CAD to assess the value of colchicine
for preventing cardiovascular events. Hard cardiovascular
events occurred in only 5.3% of those in the colchicine group
as opposed to 16% of those without this therapy. These data
support a possible prophylactic role for colchicine in patients
with stable coronary disease. In an accompanying editorial,
Vogel and Forrester (94) point out that colchicine may be
a prototype agent to show the true beneﬁts of anti-
inﬂammatory therapy in patients with coronary disease.
The role of cost effectiveness of statins for primary car-
diovascular prevention in CKD was evaluated by Erickson
et al. (95). Patients with CKD clearly have an elevated risk
of MI or stroke. The researchers found that statins were cost
effective in reducing events in patients with cardiovascular
risk but that the value was somewhat offset by the risk of
rhabdomyolysis.
The AIM-HIGH (Atherothrombosis Intervention in
Metabolic Syndrome With Low HDL/High Triglycerides
and Impact on Global Health Outcomes) trial randomly
assigned patients taking simvastatin and/or ezetimibe to
extended-release niacin (ERN) 1,500 to 2,000 mg or min-
imal immediate-release niacin (150 mg) as placebo at
bedtime (96). Low-density lipoprotein cholesterol (LDL-C)
levels in both groups were maintained from 40 to 80 mg/dl.
During a 3-year follow-up of 3,414 patients, cardiovascular
outcomes were not associated with ERN in any baseline
lipoprotein tertile. In a subset of patients in both the highest
triglyceride (198 mg/dl) and lowest high-density
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ERN showed a trend toward beneﬁt (HR: 0.74; p ¼ 0.073).
In-trial LDL-C levels, non–HDL-C levels, and the total
cholesterol/HDL-C ratios were positively associated with
cardiovascular events in the control group, but these re-
lationships were absent in the ERN group. In a second
substudy, baseline apolipoprotein (apo) B and the apoB/
apoA-I ratio were signiﬁcantly predictive of cardiovascular
events only for the placebo group. Baseline and on-study
lipoprotein(a) were predictive of cardiovascular events in
both simvastatin plus placebo and the simvastatin plus ERN
group. The ERN modestly increased 1-year apoA-1 (7%),
decreased apoB (13%), decreased the apoB/apoA-1 ratio
(19%), and decreased lipoprotein(a) (21%), but did not
reduce cardiovascular events (97). These data further
diminish the role of niacin for reducing cardiovascular risk.
ETC-1002 is a small molecule inhibitor of adenosine
triphosphate-citrate lyase and adenosine monophosphate–
activated protein kinase that modulates pathways of
cholesterol, fatty acid, and carbohydrate metabolism and
may have therapeutic beneﬁts in treating hypercholester-
olemia and other cardiometabolic risk factors. A multicenter,
randomized, double-blind, placebo-controlled, parallel-
group trial evaluated 177 patients with elevated LDL-C
(130 to 220 mg/dl) and with normal (<150 mg/dl) or
elevated (150 to <400 mg/dl) triglyceride levels, and
randomly assigned them to receive 40, 80, or 120 mg of
ETC-1002 or placebo daily for 12 weeks. The ETC-1002
signiﬁcantly lowered LDL-C levels up to 27% across a
broad range of baseline triglycerides and was generally safe
and well tolerated (98).
LDL-C is routinely estimated by the Friedewald equation
to guide treatment, but compatibility with direct LDL-C
measurements, especially at levels <70 mg/dl, is not well
established. A study examined a total of 1,310,440 patients
(191,333 patients with Friedewald LDL-C <70 mg/dl) who
underwent lipid proﬁling by vertical spin density gradient
ultracentrifugation. A greater difference in the Friedewald
estimated versus directly measured LDL-C occurred at
lower LDL-C and higher triglyceride levels. If the Friede-
wald estimated LDL-C was <70 mg/dl, the median directly
measured LDL-C was 9.0 mg/dl higher when triglyceride
levels were 150 to 199 mg/dl, and 18.4 mg/dl higher when
triglyceride levels were 200 to 399 mg/dl. Of patients with
a Friedewald estimated LDL-C <70 mg/dl, 23% had a
directly measured LDL-C 70 mg/dl (39% if triglyceride
levels were concurrently 150 to 199 mg/dl; 59% if triglyc-
eride levels were concurrently 200 to 399 mg/dl). The in-
vestigators concluded that the Friedewald equation tends
to underestimate LDL-C, particularly in patients with tri-
glyceride levels >150 mg/dl (99). In a similar cohort, sig-
niﬁcant patient-level discordance between non–HDL-C
and LDL-C was also noted. The LDL-C cutpoints of
70, 100, 130, 160, and 190 mg/dl were in the same popu-
lation percentiles as non–HDL-C values of 93, 125, 157,
190, and 223 mg/dl, respectively. Non–HDL-C reclassiﬁeda signiﬁcant proportion of patients within a higher treatment
category compared with Friedewald LDL-C, especially at
LDL-C levels in the treatment range of high-risk patients
and at triglyceride levels 150 mg/dl. Of patients with
LDL-C <70 mg/dl, 15% had a non–HDL-C 100 mg/dl
and 25% had a non–HDL-C 93 mg/dl (percentile-based
cutpoint), 22% and 50%, respectively, if triglycerides were
concurrently 150 to 199 mg/dl. Current non–HDL-C
cutpoints for high-risk patients may need to be lowered to
match percentiles of LDL-C cutpoints. Relatively small
absolute reductions in non–HDL-C cutpoints result in
substantial reclassiﬁcation of patients to higher treatment
categories with potential implications for risk assessment
and treatment (100).
Diagnosis of metabolic syndrome (MetS) is usually made
under stable conditions, because acute stress can affect its
individual components. Arnold et al. (101) evaluated the
implications of diagnosing the MetS during and 1 month
after acute myocardial infarction (AMI) in 1,129 patients
from the TRIUMPH (Translational Research Investigating
Underlying Disparities in AMI Patients’ Health Status)
registry. MetS was diagnosed in 69% of patients during
hospitalization, and in 66% 1 month after recovery, with a
cross-over in 22% (MetS diagnosed either on initial hospi-
talization or 1 month after the AMI, but not at both times).
The 12-month survival free of death or rehospitalization was
best for patients without MetS and worst for MetS present 1
month after discharge. The MetS diagnosed during initial
hospitalization conferred a poorer outcome, even if criteria
for the MetS were no longer present after 1 month. Thus,
the diagnosis of MetS has prognostic values, even during an
AMI.
Excessive dietary sodium intake has adverse cardiovascular
outcomes related to elevated BP or other factors, such as
vascular endothelial dysfunction. Jablonski et al. (102)
evaluated dietary sodium and vascular function in 17 mid-
dle age and older subjects with moderately elevated systolic
BP (130 to 159 mm Hg) in a double-blind, placebo-
controlled, randomized cross-over study. Subjects were
placed on 4 weeks of a low-sodium (1,200 mg/day) diet
(similar to the DASH diet recommended by Dietary Ap-
proaches to Stop Hypertension) or a normal-sodium diet
(3,600 mg/day), with dietary sodium intake veriﬁed by
measuring urinary sodium. The low-sodium diet improved
endothelial function in both conduit arteries (brachial artery
ﬂow mediated dilation) and resistance vessels (endothelium-
dependent dilation in response to acetylcholine). That was
related to increased nitric oxide and tetrahydrobiopterin
(BH4) bioactivity, and reduced oxidative stress. This study
demonstrates that mild endothelial dysfunction related to
age and hypertension improves with a low-sodium diet.
In an editorial comment, Celermajer and Neal (103) note
that “normal” levels of sodium intake (3,000 to 4,500 mg
daily) may be an aberration of modern society, and
contribute to adverse effects on BP, ventricular ﬁbrosis, and
renal damage. Although this study does not conclusively
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sodium intake are related to or independent of BP, it sug-
gests that lowering dietary sodium intake can provide sub-
stantial health beneﬁts.
Obesity is a major risk factor for all-cause mortality,
particularly from cardiovascular disease. Weight loss after
bariatric surgery decreases cardiovascular mortality, but the
mechanisms are unknown. Bigornia et al. (104) examined
the effects of weight loss on vascular function in 208 over-
weight or obese patients treated with medical/dietary in-
terventions or bariatric surgery (one-half in each group).
After 1 year, 112 subjects achieved >10% weight loss
(mostly from the bariatric surgery group) with improved
metabolic parameters, including decreased insulin and less
insulin resistance. That was associated with improved brachial
artery macrovascular function (measured by ﬂow-mediated
vasodilation) and microvascular function (measured by hy-
peremic blood ﬂow). Improvements in vascular function
occurred only in patients with higher baseline plasma insulin
levels (above median values before weight loss). Improvements
in vascular dysfunction and insulin resistance with weight loss
may be the mechanism for reduced cardiovascular risks. In
an accompanying editorial, Anderson (105) notes that in the
face of the global health epidemic of obesity, this study pro-
vides valuable information on how weight loss may improve
vascular function, a surrogate marker for cardiovascular risk.
It may require a large (>10%) weight loss and/or bariatric
surgery to achieve this result, as other studies with more
modest (5% to 7%) weight loss failed to show improvements
in large vessel function. Of note, insulin levels below median
value (<12 mIU/ml) in this study are higher than in healthy
subjects (4 to 6 mIU/ml), but this group did not improve
vascular function despite >10% weight loss. Insulin may be a
biomarker for the beneﬁcial effects of weight loss on vascular
function.
The ventricle and arterial circulation interact by
ventricular-arterial coupling relationships that affect both
systolic and diastolic function. Safar et al. (106) review how
these interactions vary with age, sex, and disease. There is
a progressive age-dependent increase in systolic, mean, and
diastolic BP, but diastolic BP falls after ages 45 to 55 years
with age-dependent decreases in arterial distensibility.
Aortic pulse wave velocity, a surrogate measure of aortic
stiffness, increases with age and diseases such as MetS, and
is a predictor of overall and cardiovascular risk. There are
sex-related differences in aortic stiffness due to hormonal
factors (e.g., high estrogen causes vascular relaxation) and
nonhormonal factors, such as differences in height, heart
rate, and cardiac output.
Coutinho et al. (107) postulated that sex-dependent dif-
ferences in arterial stiffness predispose to diastolic dysfunc-
tion or heart failure with preserved ejection fraction
(HFpEF), which is more prevalent among women. Pulsatile
load on the left ventricle was measured in 272 women and
189 men (average age 65 to 67 years) without HF. There
was higher aortic characteristic impedance (Zc) and lowertotal arterial compliance in women than men. The higher Zc
and lower total arterial compliance were associated with
diastolic dysfunction in women, but not in men. Greater
proximal aortic stiffness (higher Zc) may cause a relative
afterload mismatch that predisposes to HFpEF in women.
O’Rourke and Safar (108) opined that these sex-related
differences were due to the smaller body size of women,
and shorter body lengths result in earlier return of wave
reﬂection with greater augmentation of aortic pressures in
women. Coutinho et al. (109) replied that their multivariable
model took into account scaling differences, and Zc
remained higher in women after adjusting for differences in
aortic size. Also diastolic dysfunction was associated with
early systolic load (Zc), and not peripheral reﬂection or late
systolic load (109).
Future studies are needed to prove a causal relationship
between altered ventricular-arterial coupling and HFpEF to
determine if this may be a potential therapeutic target.
PAD can be diagnosed by the ABI. Current guidelines
use the higher value of the dorsalis pedis or posterior tibial
ankle artery, and the higher brachial artery pressure
measured from either arm. An abnormal ABI of <0.90
identiﬁes PAD patients; this has been associated with
increased risk of major adverse cardiovascular events. Nead
et al. (110) evaluated an alternative measure of ABI in 1,413
subjects from the GenePAD (Genetic Determinants of
Peripheral Artery Disease) study, referred to 2 medical
centers for elective coronary artery catheterization. The ABI
was measured by the traditional method, as well as by an
alternative method using the lower (rather than higher)
of the dorsalis pedis or posterior tibial ankle pressure. PAD
was diagnosed in 224 subjects by the traditional ABI
method (16% prevalence), and in 282 by the alternative ABI
method (20% prevalence), with no overlap of patients
between groups. Both PAD groups had higher all-cause and
cardiovascular mortality over a median follow-up of 5 years.
This alternative ABI method identiﬁed a sizable group
of patients with PAD with increased mortality who would
have been missed if the investigators had relied only on the
traditional ABI method. Hiatt (111), in an editorial
comment, notes that a substantial number of patients with
PAD identiﬁed by the alternative ABI method had
increased mortality. However, there may be a selection bias,
as all patients were referred for evaluation of CAD. It will be
important to determine whether the alternative ABI index
has similar prognostic value for a lower-risk group.
Heart rhythm disorders. Steven et al. (112) evaluated the
beneﬁt of pulmonary vein isolation guided by loss of pace
capture on the ablation line in a prospective 2-center ran-
domized trial (n ¼ 102) to determine whether this approach
improved outcomes after radiofrequency ablation of atrial
ﬁbrillation (AF). In group 1 (n ¼ 50), the procedural
endpoint was bidirectional block across the ablation line,
whereas in group 2 (n ¼ 52), additional inexcitability to bi-
polar pacing along the ablation line was required. The primary
endpoint was freedom from any atrial ﬁbrillation/atrial
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discontinuation of antiarrhythmic drugs. Procedural end-
points were achieved in all patients, and procedure duration
was signiﬁcantly longer for group 2, although ﬂuoroscopy
times were not different. After 12 months, 52% patients in
group 1 versus 82.7% (n ¼ 43) in group 2 were free from any
AF/AT (p ¼ 0.001) after a single procedure. No major
complications occurred. The researchers concluded that the
use of pacing to ensure inexcitability along the pulmonary vein
isolation line improved short-term, single procedure success,
compared with demonstration of bidirectional block alone.
Wu et al. (113) conducted a meta-analysis to evaluate the
risk and incidence of arrhythmic, cardiac, and all-cause
death in a general population with early repolarization
pattern (ERP) on ECG, which has been associated with
vulnerability to ventricular ﬁbrillation. The relative risks of
ERP were 1.70 (95% CI: 1.19 to 2.42; p ¼ 0.003) for
arrhythmia death, 0.78 (95% CI: 0.27 to 2.25; p ¼ 0.63) for
cardiac death, and 1.06 (95% CI: 0.87 to 1.28; p ¼ 0.57) for
all-cause death. The estimated absolute risk differences of
subjects with ERP were 70 cases of arrhythmia death per
100,000 subjects per year. J-point elevation in inferior leads
and QRS notching were associated with an increased risk of
arrhythmic death. The researchers concluded that ERP was
associated with increased risk of arrhythmic death, but that
further study is needed to clarify which subgroups with ERP
are at highest risk of arrhythmia death. The mechanism by
which ERP increases the risk of arrhythmic death is also
unknown.
James et al. (114) evaluated the exercise patterns of carriers
of desmosomal mutations responsible for arrhythmogenic
right ventricular dysplasia/cardiomyopathy (ARVD/C) to
determine how exercise inﬂuences penetrance among pa-
tients with such mutations. Regular physical activity from age
10 years was assessed in 87 carriers to correlate exercise with
sustained ventricular arrhythmia (ventricular tarchycardia/
ventricular ﬁbrillation [VT/VF]), HF, and diagnostic criteria
for ARVD/C (2010 Revised Task Force Criteria [TFC]).
They determined that endurance athletes (n ¼ 56) had
symptoms develop at a younger age (30 years vs. 40 years; p¼
0.05), were more likely to meet TFC at last follow-up, and
had a lower lifetime survival free from VT/VF and HF.
Compared to persons with the lowest quartile exercise the
year before presentation, those in the other quartiles were
more likely to meet TFC. Among 61 patients who did not
present with VT/VF, the 13 subjects experiencing a ﬁrst VT/
VF event over during 8.4  6.7 years of follow-up were all
endurance athletes (p ¼ 0.002). Survival after the ﬁrst VT/
VF event was lowest among those who exercised at the
highest level (top quartile) both before and after clinical
presentation. Among patients in the top quartile, a reduction
in exercise decreased VT/VF risk (p ¼ 0.04). The in-
vestigators concluded that endurance exercise and frequent
exercise both increase risk of VT/VF, HF, and ARVD/C in
desmosomal mutation carriers. They also concluded that
their ﬁndings support exercise restriction for these patients.Powell et al. (115) sought to determine whether the
mortality risk associated with inappropriate implantable
cardioverter-deﬁbrillator (ICD) shocks is due to the un-
derlying arrhythmia or to the shock itself. The researchers
evaluated survival outcomes of ICD and cardiac resynchro-
nization therapy with deﬁbrillation (CRT-D) patients
enrolled in the LATITUDE remote monitoring system
(Boston Scientiﬁc, Natick, Massachusetts). First shock
episode rhythms from 3,809 patients who acutely survived
the initial shock were adjudicated by 7 electrophysiologists.
Patients with a shock were matched to patients without a
shock by age at implant, implant year, sex, and device type.
Compared to no shock, there was increased mortality among
patients who received their ﬁrst shock for monomorphic
ventricular tachycardia (HR: 1.65; p < 0.0001), ventricular
ﬁbrillation or polymorphic ventricular tachycardia (HR:
2.10; p < 0.0001), and AF or atrial ﬂutter (HR: 1.61; p ¼
0.003). In contrast, mortality after a ﬁrst shock due to sinus
or supraventricular tachycardia (HR: 0.97; p ¼ 0.86), noise,
artifact, or over-sensing (HR: 0.91; p ¼ 0.76) was compa-
rable to that of patients without a shock. Thus, the re-
searchers concluded that the adverse prognosis after a ﬁrst
shock appears to be related more to the underlying
arrhythmia, rather than to an adverse effect of the shock
itself. This area remains controversial as other reports have
suggested that any shock, appropriate or inappropriate, may
be associated with increased mortality risk.
Ruwald et al. (116) assessed the impact of carvedilol
and metoprolol on inappropriate ICD therapy in the
MADIT-CRT (Multicenter Automatic Deﬁbrillator Im-
plantation Trial-Cardiac Resynchronization Therapy) trial.
All patients in the MADIT-CRT study who received a
device (n ¼ 1,790) were identiﬁed, and the effect of different
beta-blockers or no beta-blockers was compared for the
primary endpoint of inappropriate therapy including anti-
tachycardia pacing and shocks and the secondary endpoint
of inappropriate therapy for AF or atrial tachyarrhythmias.
Inappropriate device therapy occurred in 253 of 1,790 pa-
tients (14%) during a mean follow-up period of 3.4 years.
Carvedilol was associated with a signiﬁcantly lower risk of
inappropriate therapy compared with metoprolol (HR: 0.64;
p ¼ 0.002), including both antitachycardia pacing and
shocks, as well as the risk of inappropriate therapy caused by
AF. General use of beta-blocker (93%) and adherence to
therapy in this study was high. The mechanisms by which
carvedilol produced these better outcomes compared with
metoprolol are not known, but could be in part due to the
differential pharmacological effects.
Ruwald et al. (117) also evaluated all patients receiving
either metoprolol or carvedilol in the MADIT-CRT study
for differences in HF hospitalization or death and ventricular
arrhythmias. Hospitalization for HF or death occurred in
30% of the patients on metoprolol and in 23% on carvedilol
(HR: 0.70; p ¼ 0.001). This carvedilol advantage was also
observed in CRT-D patients without and with left bundle
branch block, in whom ventricular arrhythmias occurred in
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respectively (HR: 0.80; p ¼ 0.050). There was a dose-
dependent relationship in risk reduction demonstrated
with carvedilol, but not with metoprolol.
Early repolarization on the ECG, once thought to be
entirely benign, is now known to be associated with ven-
tricular arrhythmias in some patients who are designated as
having early repolarization syndrome (ERS). To identify
whether ERS is inheritable, Gourraud et al. (118) screened
relatives of 4 families affected by ERS; ECG early repolar-
ization was deﬁned as a distinct J-wave in at least
2 consecutive leads 1 mm above baseline. The investigators
found 22 sudden cardiac deaths, including 10 before 35
years of age, and the families had a prevalence of ECG early
repolarization of 34% to 61%. The mode of inheritance was
compatible with autosomal dominant, but no known ERS-
associated genes were found in probands. Furthermore, the
Valsalva maneuver was performed in 80 relatives and was
found to increase J-wave amplitude in 17 of 20 affected
patients and uncover early repolarization in 17 relatives. The
investigators concluded that ERS can be inherited by
autosomal dominant transmission, and that ECG early
repolarization can be uncovered by the Valsalva maneuver.
An accompanying editorial by Krahn et al. (119) cautioned
readers to interpret these results in the context of a low
prevalence of ERS compared to benign forms of ECG early
repolarization.
Although guidelines for the ICD are well established,
those for the wearable cardioverter-deﬁbrillator (WCD) are
less clear. Epstein et al. (120) investigated the effectiveness
of the WCD in patients with recent revascularization after
MI, for whom guidelines recommend postponement of
immediate ICD implantation. Between September 2005
and July 2011, the researchers discovered 8,453 unique pa-
tients, of whom 133 (1.6%) received appropriate shocks and
91% were resuscitated from a ventricular arrhythmia. Left
ventricular ejection fraction in patients receiving a shock
was 30% in 106, 30% to 35% in 17, and >36% in 8 (not
reported in 2). Of treated patients, 75% received treatment
in the ﬁrst month and 96% in the ﬁrst 3 months, with a
median time to therapy of 16 days. Shock success resulting
in survival was 84% in nonrevascularized patients and 95%
in revascularized patients. The researchers conclude that
during the currently indicated 40-day and 3-month waiting
periods after MI, the WCD successfully treated sudden
cardiac arrest (SCA) in 1.4%, with the highest risk in the
ﬁrst month.
Packer et al. (121) reported the results of STOP-AF
(North American Arctic Front Pivotal Trial), a multi-
center randomized controlled trial of cryoballoon ablation,
a novel freezing balloon that can be engaged in each pul-
monary vein, theoretically to enable isolation with 1 appli-
cation, versus antiarrhythmic medications. The investigators
randomly allocated 245 AF patients (paroxysmal 78%) who
were resistant to at least 1 antiarrhythmic medication 2:1 to
cryoballoon or drug therapy, and assessed results after a 90-day blanking period. Cryoablation successfully isolated all
pulmonary veins in 97.6% of patients, withz14% requiring
use of an additional radiofrequency catheter. At 12 months,
treatment success deﬁned as freedom from AF, use of a non-
study antiarrhythmic drug, or any additional ablation, was
69.9% in cryoablation patients (57.7% single procedure
including 8% using drugs) versus 7.3% in antiarrhythmic
drug patients (p < 0.001). Cryoablation also signiﬁcantly
improved symptoms versus drug therapy. The investigators
concluded that the STOP AF trial showed that cryoballoon
ablation is a safe and effective alternative to antiarrhythmic
medication for the treatment of patients with symptomatic
paroxysmal AF.
In a parallel study, Vogt et al. (122) studied the long-term
freedom from AF using cryoablation, but tailored the
cryoballoon to each patient’s pulmonary vein size. This
prospective observational study involved 605 consecutive AF
patients (paroxysmal, n ¼ 579). Pulmonary vein isolation
was achieved without an additional catheter in 91.1% of
patients. Follow-up data for >12 months were available for
451 patients, in whom AF freedom was 61.6%, with success
after repeat procedures rising to 76.9%. The researchers
concluded that long-term freedom from AF after cry-
oballoon ablation is similar to reports from radiofrequency
ablation, and that individualizing balloon size may improve
outcomes. These 2 studies were synthesized in an accom-
panying editorial by Ernst (123), in the context of other
challenges to AF ablation and recent approaches published
in the Journal in 2013, including ablation at recently iden-
tiﬁed sources for AF (rotors) that may lie at widespread
patient-speciﬁc locations in either atrium (124).
One potentially troubling result from the ROCKET AF
(Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition
Compared With Vitamin K Antagonism for Prevention
of Stroke and EmbolismTrial in Atrial Fibrillation), in which
rivaroxaban was noninferior to warfarin for preventing stroke
in 14,624 AF patients (125), was that rivaroxaban-treated
patients had a higher rate of stroke/thromboembolism at
study end versus patients treated with warfarin. This led to a
black box warning by the Food and Drug Administration.
Patel et al. (126) studied this issue by examining stroke or
non–central nervous system embolism within 30 days after
temporary interruptions of 3 days or more, early permanent
study drug discontinuation, and end-of-study transition to
open-label therapy. Thromboembolic events occurred at
similar rates after temporary interruptions (p ¼ 0.62) and
permanent discontinuation (p ¼ 0.66). However, on tran-
sitioning to open-label warfarin at the study end, patients
assigned to rivaroxaban had more strokes (n ¼ 22) than pa-
tients on warfarin (n¼ 6) (6.42 per 100 patient-years vs. 1.73
per 100 patient-years; HR: 3.72, 95% CI: 1.51 to 9.16; p ¼
0.004), and took longer to reach a therapeutic international
normalized ratio. Unexpectedly, patients using rivaroxaban
also had a higher bleeding rate in this timeframe (7.3 events
vs. 2.0 events per 100 patient-years, p ¼ 0.003). The
researchers concluded that the increased risk of stroke and
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patients at study end resulted from inferior transitioning to
vitamin-K antagonist therapy that uncovered their baseline
thromboembolic risk, rather than a true “rebound” from
rivaroxaban. The accompanying editorial by Reynolds (127)
discusses these points, and the unresolved issue of why such
patients also experienced a higher bleeding risk.
Prescribing antithrombotic therapy is particularly chal-
lenging for AF patients with coronary disease and in-
dications for antiplatelet agents. Lamberts et al. (128)
performed an observational study of 12,165 AF patients
who were hospitalized with MI and/or undergoing PCI
between 2001 and 2009 in a Danish registry to investigate
the relationship between antithrombotic therapy and
outcome. Compared to triple therapy (oral anticoagulation
[OAC] plus aspirin plus clopidogrel), there was no increased
risk of recurrent coronary events for OAC plus clopidogrel
(HR: 0.69), OAC plus aspirin (HR: 0.96), or aspirin plus
clopidogrel (HR: 1.17). Aspirin plus clopidogrel was asso-
ciated with a higher risk of ischemic stroke (HR: 1.50), and
OAC plus aspirin or aspirin plus clopidogrel were associated
with a signiﬁcant increased risk of all-cause death (HR:
1.52). Compared to triple therapy, bleeding risk was
nonsigniﬁcantly lower for OAC plus clopidogrel (HR: 0.78)
and signiﬁcantly lower for OAC plus aspirin and aspirin plus
clopidogrel. The researchers concluded that OAC plus
clopidogrel was equal to or better than triple therapy on both
beneﬁt and safety outcomes. An accompanying editorial
(129) placed the results of this study in context of other
studies, including the recent WOEST (What Is the
Optimal Antiplatelet and Anticoagulant Therapy in Patients
With Oral Anticoagulation and Coronary Stenting) trial
(130), which also favored OAC plus clopidogrel over triple
therapy for such patients.
The mechanisms acutely linking AF with thromboem-
bolism are not fully understood, but were addressed by
several papers. Lim et al. (131) studied serum and atrial
blood markers of thrombosis in 55 AF patients undergoing
induced AF, with rapid paced rates (not AF), and who
remained in sinus rhythm (to study the impact of trans-
septal cannulation), and in a reference group of n ¼ 15
patients without clinical AF (left-sided accessory pathway).
The investigators found that markers of platelet activation
and left atrial thrombin generation measured acutely at
electrophysiology study increased in the AF and pacing
groups, particularly in left atrium, but fell in control patients.
Markers of platelet reactivity increased in patients in AF but
not in patients during pacing nor in control patients. These
results have implications for the acute pathophysiology of
thrombogenesis after AF, and thus for clinical risk.
It has long been clinical practice to cardiovert patients
with acute AF (<48 h duration) without anticoagulation
therapy, based largely on anecdotal data. Airaksinen et al.
(132) studied the safety of this approach in the Fin CV
(Finnish CardioVersion) study, in which they examined
embolic complications up to 30 days after 7,660cardioversions in 3,143 patients. They detected 38 “deﬁnite”
thromboembolic events and 4 transient ischemic events, for
a total of z0.8%. This risk was not uniform between pa-
tients and, remarkably, ranged from 9.8% among patients
with HF and diabetes mellitus, to as low as 0.2% among
patients without HF and age <60 years. These data suggest
that cardioversion of even acute AF should be performed
with caution, potentially using anticoagulation therapy for
patients with speciﬁc risk factors. The implications of these
ﬁndings, and their relationship to emerging guidelines, were
discussed in the editorial by Dagres et al. (133).
In type 2 diabetic patients, one-fourth of strokes are of
unknown cause. Marfella et al. (134) studied whether sub-
clinical AF was associated with an increased risk of silent
cerebral infarct and stroke in diabetic patients <60 years of
age with no clinical evidence of AF or cerebrovascular disease.
In a longitudinal observational study, 464 type 2 diabetic
patients <60 years of age were studied by quarterly 48-h
ambulatory ECGs (8 days of recording per year) to detect
brief (<48-h) AF episodes in relation to the outcomes of si-
lent cerebral infarct, detected byMRI of the brain, and stroke.
The investigators found that subclinical AF was signiﬁcantly
more prevalent among diabetic patients than matched healthy
subjects (11% vs. 1.6%; p< 0.0001). On 37months of follow-
up, diabetic patients with silent AF had a higher prevalence of
silent cerebral infarct (61% vs. 29%; p < 0.01) and of stroke
events (17% vs. 5%; p < 0.01) in follow-up than patients
without AF. Accordingly, silent AF independently deter-
mined silent cerebral infarct (OR: 4.4; p < 0.001) and stroke
(HR: 4.6; p < 0.01) in diabetic patients.
Another troubling concept is the potential link of AF
with dementia (135). Noninvasive imaging has shown a
7% to 14% prevalence of subclinical cerebral events after AF
ablation (136), in addition to lesions seen in AF patients
without intervention, and although “subclinical,” their
functional signiﬁcance is unclear. Medi et al. (137) studied
functionally whether post-operative neurocognitive
dysfunction occurs after AF ablation in 150 patients mostly
with CHADS2 scores (Congestive heart failure, Hyperten-
sion, Age 75 years, Diabetes mellitus, previous Stroke/
transient ischemic attack) of 0 to 1, of whom 60 underwent
ablation for paroxysmal AF, 30 for persistent AF, and 30 for
supraventricular tachycardia, compared with a matched
nonoperative control of AF patients awaiting ablation (n ¼
30). Notably, post-operative neurocognitive dysfunction at
day 2 was present in more patients with AF (28% parox-
ysmal AF, 27% persistent AF) than supraventricular tachy-
cardia (13%) or controls not undergoing procedures (0%;
p ¼ 0.007). At day 90, this trend continued and, on uni-
variate analysis, was associated with left atrial access time.
The investigators concluded that AF ablation is associated
with a 13% to 20% prevalence of post-operative neuro-
cognitive dysfunction, whose long-term implications require
further study.
Bartus et al. (138) reported an initial experience of the
LARIAT suture delivery device (SentreHEART, Redwood
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guided epicardially through percutaneous access to occlude
the left atrial appendage (LAA). A total of 85 (96%) of 89
patients underwent successful LAA ligation, of whom 81
had complete closure measured by TEE. Three access-
related complications were reported, with adverse events
including severe pericarditis (n ¼ 2), late pericardial effusion
(n ¼ 1), unexplained sudden death (n ¼ 2), and late stroke
(n ¼ 2). On repeat TEE at 1 and 3 months after ligation,
95% of patients had complete LAA closure. Of the 65 pa-
tients undergoing 1-year TEE, there was 98% complete
LAA closure, including patients with previous leaks. The
researchers concluded that LAA closure with the LARIAT
device can be performed effectively with acceptable rates of
complications and adverse events.
In the ASAP (ASA Plavix Feasibility Study With
Watchman Left Atrial Appendage Closure Technology)
study, Reddy et al. (139) reported on the safety and efﬁcacy of
LAA closure with an endocardial Watchman device (Boston
Scientiﬁc, Natick, Massachusetts) in 150 nonvalvular AF
patients ineligible for warfarin therapy. This population
contrasts with patients in the pivotal PROTECT-AF
(Percutaneous Closure of the Left Atrial Appendage
Versus Warfarin Therapy for Prevention of Stroke in Pa-
tients with Atrial Fibrillation) study who were candidates for
and actually received warfarin for 6 weeks post-procedure.
Serious procedure- or device-related safety events occurred
in 8.7% of patients. Over 14 months of follow-up, all-cause
stroke or systemic embolism occurred in 4 patients (2.3% per
year) (ischemic stroke in 3 patients [1.7% per year] and
hemorrhagic stroke in 1 patient [0.6% per year]) providing an
ischemic stroke rate lower than expected (7.3% per year)
based on the CHADS2 scores. The researchers concluded
that LAA closure with the Watchman device can be safely
performed without the use of warfarin, and is a reasonable
alternative in patients at high risk for stroke with contrain-
dications to systemic oral anticoagulation therapy.
In a third study, Ohtsuka et al. (140) report on the safety
and efﬁcacy of surgical, stand-alone thoracoscopic left atrial
appendectomy to prevent thromboembolism in 30 patients
with nonvalvular AF, of whom 21 urgently needed an alter-
native to anticoagulation therapy. This minimally-invasive
procedure took an average of 32 min (and was switched
to minithoracotomy in 2 cases), with no mortality or major
complications. Complete appendectomy was conﬁrmed
by CT at 3 months. On follow-up at 16 months off anti-
coagulation therapy, no patients had thromboembolic events.
The researchers concluded that thoracoscopic stand-alone
surgical appendectomy is potentially safe and allows com-
plete LAA closure.
All 3 studies on LAA occlusion were placed in context in
the editorial by Turi (141), discussing the early stage of the
ﬁeld of appendage occlusion and the need for larger,
multicenter studies of safety and efﬁcacy of each approach.
The PROTECT-AF trial showed that LAA closure with
the Watchman device was noninferior to warfarin in patientswith nonvalvular AF and a CHADS2 score of 1 (142).
Investigators subsequently examined quality of life indicators
in this study. They found that the physical score improved in
34% of patients with the device and was unchanged in 29%
compared with warfarin, with values of 24.7% and 31.7%,
respectively (p < 0.01). Thus, patients with nonvalvular AF
at risk for stroke had a more favorable quality of life with the
LAA device than with warfarin.
The role of omega-3 fatty acids for the prevention of
recurrent AF remains uncertain. Therefore, Macchia et al.
(143) conducted FORWARD (Randomized Trial to Assess
Efﬁcacy of PUFA for the Maintenance of Sinus Rhythm in
Persistent Atrial Fibrillation). This prospective, randomized,
controlled multicenter trial in patients with symptomatic
paroxysmal AF randomly assigned 586 patients to poly-
unsaturated fatty acids for 12 months for a primary endpoint
of symptomatic recurrent AF. This study did not ﬁnd any
differences in the primary endpoint in the patients treated
with n-3 polyunsaturated fatty acids versus placebo, thus
indicating that such a treatment is not justiﬁed.
The potential link between mitochondrial dysfunction
and AF was studied in post-operative AF patients with
MetS (144). Mitochondrial respiration and calcium reten-
tion capacity, respiratory complex activity, and myocardial
oxidative stress were quantiﬁed in right atrial tissue obtained
in 104 patients with MetS undergoing CABG. The in-
vestigators found decreased pre-operative mitochondrial
respiration and increased sensitivity to calcium-induced
mitochondrial permeability transition pore opening in the
44% of patients who had post-operative AF. Accordingly,
these studies identiﬁed an association between pre-operative
mitochondrial dysfunction of atrial myocardium and the
occurrence of AF after surgery. In an accompanying
editorial, Brown and Moukdar (145) commented that an
interesting question arising from this study is whether the
long-term morbidity/mortality associated with AF is due to
the AF directly or is just a manifestation of unhealthy tissue
mitochondria. They further pointed out that the study
opened the door for potential therapies to prevent a post-
operative AF by targeting mitochondria.
Obstructive sleep apnea is being increasingly recognized
as an important issue in regard to cardiovascular disease.
Therefore, Gami et al. (146) conducted a study to determine
whether there was an increased risk of sudden cardiac death
associated with obstructive sleep apnea. They retrospectively
evaluated 10,701 adult patients undergoing ﬁrst diagnostic
polysomnogram followed up for as long as 15 years (average
5.3 years) and found that sudden cardiac death was best
predicted by age >60 years, apnea-hypopnea index >20,
mean nocturnal oxygen saturation <93%, and lowest
nocturnal oxygen saturation <78%. They concluded that
their ﬁndings implicated obstructive sleep apnea as a novel
risk factor for sudden cardiac death.
It is well recognized that randomized clinical trials have
the limitation that many patients with comorbidities seen in
the real world are often excluded. Therefore, Larsen et al.
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Danish Registry of Medicinal Product Statistics to compare
the value of dabigatran to warfarin in propensity-matched
patients treated in everyday clinical practice. They demon-
strated that stroke and systemic embolism were not signiﬁ-
cantly different in warfarin- and dabigatran-treated patients,
and that adjusted mortality was signiﬁcantly lower with
dabigatran doses of both 110 and 150 mg bid. Less intra-
cranial bleeding was seen with both dabigatran doses. Of
importance, the incidence of MI was lower with both
dabigatran doses.
Heart failure. Concepts regarding HFpEF continue to
evolve. Paulus and Tschöpe (148) present a new paradigm
for the development of HFpEF in which comorbidities such
as salt-sensitive hypertension, diabetes, obesity, and chronic
pulmonary disease give rise to a systemic proinﬂammatory
state in which coronary microvascular endothelial inﬂam-
mation reduces availability of nitric oxide, cyclic guanosine
monophosphate (cGMP), and protein kinase G activity in
adjacent cardiomyocytes. Low protein kinase G activity, in
turn, is related to hypophosphorylation of the giant molecule
titan in cardiomyocytes and development of hypertrophy
and increased resting tension within the heart. The resultant
increase in cardiomyocyte stiffness and interstitial ﬁbrosis
combine to increase LV stiffness and lead to the develop-
ment of HF. This paradigm shifts the focus from LV
afterload to events in the coronary microvasculature in
HFpEF, and it opens new avenues for diagnosing and
treating patients with this condition. In the accompanying
editorial, Desai (149) reminds us that while awaiting results
of studies providing evidence in support of this paradigm,
compelling rationale for the aggressive treatment of hyper-
tension and comorbidities to prevent or forestall the onset of
HFpEF already exists.
Although endurance exercise training has been shown to
increase exercise capacity in HFpEF patients (150), the
mechanisms involved remain uncertain. To assess the effects
of exercise training on ﬂow-mediated vasodilation and ca-
rotid artery stiffness and their association with training-
related increases in peak VO2, Kitzman et al. (150)
assessed changes in brachial ﬂow-mediated vasodilation
and carotid artery distensibility in a cohort of older HFpEF
patients. They found that improved peak VO2 occurring
with 16 weeks of exercise training was not accompanied by
evidence of change in either systolic or diastolic functions of
the heart or in endothelial function or arterial stiffness.
These ﬁndings suggest that other mechanisms, including
enhanced skeletal muscle perfusion or oxygen utilization,
might be playing a role in the improved exercise capacity
seen with exercise training in this population. Keteyian
(151), in commenting on this paper, reinforced the concept
that future research needed to focus on the metabolism of
muscles actively involved in exercise.
To assess the impact of therapy with ivabradine on ex-
ercise capacity and LV ﬁlling parameters in HFpEF pa-
tients, Kosmala et al. (152) performed cardiopulmonaryexercise testing and echocardiography before and after 7 days
of blinded treatment with ivabradine or placebo. They found
that in comparison to placebo, ivabradine slowed the in-
crease in heart rate during exercise while increasing exercise
capacity. Of particular note, because HFpEF patients
experience symptoms mostly with exercise, was the ﬁnding
that improved exercise capacity with ivabradine was associ-
ated with improved LV ﬁlling pressures. In the accompa-
nying editorial, Shah (153) called for a longer duration,
large-scale trial of ivabradine in the HFpEF patients with
a focus on patients with early stage disease in whom exercise
intolerance is a key symptom and in whom there is objective
evidence of exercise intolerance.
Using the Nationwide Inpatient Sample, Blecker et al.
(154) evaluated trends in HF hospitalization between 2001
and 2009 in the United States. They found that whereas
the number of primary HF hospitalizations decreased over
this period, secondary HF hospitalizations increased (albeit
with a trend toward a lower number toward the end of the
period). Common diagnoses for secondary hospitalizations
included pulmonary disease, renal failure, and infections.
This information helps to emphasize the need for more
effective strategies that target both cardiac and noncardiac
conditions that result in hospitalization. The need to shift
public health focus from disease-centric approaches to
models that recognize the key role of “multimorbidities,”
particularly in the HF population, was noted by Roger (155)
in an accompanying editorial.
Chaudhry et al. (156) looked at risk factors for hospital
admission among older patients with newly-diagnosed HF
using data from the Cardiovascular Health Study. Geriatric
conditions, including slow gait, depression, and muscle
wasting, emerged as independent risk factors (along with
commonly recognized conditions such as diabetes mellitus,
NYHA functional class, CKD, and depressed ejection
fraction) for hospitalization in this population, leading the
investigators to conclude that these potentially modiﬁable
conditions should be routinely assessed at the time of HF
diagnosis. The accompanying editorial by Adamson (157),
however, noted that although it is tempting to assume that
interventions (e.g., exercise training) designed to change risk
factors may change outcomes, prospective clinical trial re-
sults in an appropriate population are needed to provide
evidence that they will be effective in doing so.
The most effective management of patients with
decompensated HF remains uncertain, particularly in view
of the high rates of post-discharge readmission and mor-
tality. Although diuretic therapy helps to decongest patients,
it has also been associated with worsening renal function,
an important predictor of outcomes in patients hospitalized
with HF. To assess the clinical correlates and prognostic role
of anemia and changes in hemoglobin in patients hospital-
ized because of decompensated HF, van der Meer et al.
(158) assessed the impact of baseline and change in hemo-
globin during HF hospitalization in patients with mild to
moderate impairment of renal function. They reported that
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independently associated with a favorable outcome, despite
a slight decrease in renal function. Commenting on these
ﬁndings, Desai (159) noted that they may be attributable to
the impact of better decongestion on clinical outcomes and
that they supported guideline recommendations for the use
of diuretics to restore normal volume states before discharge.
They also raise the possibility that changes in hemoglobin
could be used to assess the response to therapy in congested
patients.
Although aldosterone receptor antagonists have been
shown to improve outcomes in patients with HFpEF,
concerns about their safety and efﬁcacy in patients at high
risk for hyperkalemia or worsening renal function have
persisted. Eschalier et al. (160) addressed this issue in a pre-
speciﬁed analysis of patients in the EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization And SurvIval
Study in Heart Failure) study who were 75 years of age,
with diabetes, with estimated glomerular ﬁltration rate <60
ml/min/1.73 m2, and with systolic BP less than the median
of 123 mm Hg. They found that in all high-risk subgroups,
eplerenone was associated with an increased risk of potas-
sium >5.5 mmol/l but not of potassium >6.0 mmol/l.
Eplerenone was not associated with an increased incidence
of hospitalization for hyperkalemia or discontinuation of
study medication to adverse events. Moreover, eplerenone
reduced the primary composite endpoint of HF hospitali-
zation or cardiovascular mortality in these high-risk sub-
groups. While ﬁnding these results compelling, Bart and
Nelson (161) offered a cautionary note by pointing out that
patients at highest risk for drug-related adverse events were
excluded from the EMPHASIS-HF study, and that the
laboratory monitoring protocol was very structured in the
patients who were included in the trial.
From the perspective of traditional Chinese medicine,
the primary cause of HF is heart Yang deﬁciency that
results from Qi inadequacy and blood stasis. Qili qiangxin
capsules, a speciﬁc traditional Chinese medicine obtained
from 11 types of herbs, have been approved for treating HF
in China. In a multicenter, randomized, double-blind,
parallel-group, placebo-controlled study of the effects of
qili qiangxin capsules in patients with chronic HF, Li et al.
(162) reported that on a background of standard Western
therapy for HF, qili resulted in a signiﬁcantly greater
reduction in natriuretic peptide levels (the primary endpoint
of the study) than did placebo over a 12-week period. Qili
qiangxin treatment was also associated with greater
improvement in NYHA functional class, LV ejection frac-
tion, 6-min walk test distance, and quality of life than pla-
cebo. Tang and Huang (163), in an accompanying editorial,
noted that although this report may have broken the barrier
for traditional Chinese medicine to be able to provide
clinical evidence of efﬁcacy, signiﬁcant questions still
remain, including issues with the adequacy and stability of
background therapy and the exact makeup of the capsules
that were used in the study. Nonetheless, these results offerthe intriguing possibility that traditional Chinese medicine
effects may be synergistic with those obtained from Western
medicine and offer added beneﬁts to HF patients.
A paper by Drakos et al. (164) challenges the conven-
tional wisdom that recovery of function after left ventricular
assist device (LVAD) implantation is extremely rare. The
investigators followed up 80 consecutive patients after
LVAD implant prospectively and performed serial echo-
cardiograms using a “turn down” protocol in which the
impeller on the VAD was set to the minimal speed. Sur-
prisingly, after 6 months of support, 34% of patients had
relative LV ejection fraction increase above 50%, and 19%
of patients achieved an LV ejection fraction above 40%.
No regression in function was noted. The reason for the
discrepancy between this study and previous studies is that
the patients in the current study had their LVADs turned
down during their echocardiograms; hence, recovery in other
studies may have simply gone unnoticed. None of the pa-
tients had their LVADs explanted; hence, the signiﬁcance
of the recovery is uncertain. Nonetheless, given the signiﬁ-
cant increase in use of LVADs and the limited number of
donor organs available, strategies for recovery after LVAD
implantation are sorely needed. In an editorial by Silva et al.
(165), it is suggested that further study will be required to
see if aggressive use of neurohormonal therapy, or possibly
novel therapeutics, could assist in a signiﬁcant incidence of
“true” recoverydnamely, enough recovery to justify expla-
nation of the device.
It is well established that a decreased body mass index is
associated with worse outcomes among patients with HF,
although the pathophysiology of this so-called obesity
paradox is poorly understood. Previous studies suggested
that the unintentional weight loss seen in HF, also known as
cardiac cachexia, occurred primarily in patients with right
ventricular (RV) dysfunction. To evaluate the relationship
between RV function, body composition, and prognosis in
advanced HF, Melonivsky et al. (166) performed x-ray ab-
sorptiometry on patients with HF. They found that patients
with RV failure had greater weight loss and a lower fat/lean
body mass ratio. The RV failure patients with low body fat
had worse outcomes, but surprisingly this was primarily seen
in patients with lower fat, whereas lean mass was not pre-
dictive. Although most therapeutics and studies focus on LV
function, this study reinforces the morbidity associated with
RV function.
With increasing use of LVADs for a bridge to transplant
or destination therapy, there is an increasing need for an
adequate method to assess risk in patients with advanced
HF. Therefore, Cowger et al. (167) analyzed the outcome
in 1,122 patients receiving the HeartMate II LVAD for
bridge or destination therapy and divided them into deri-
vation and validation cohorts. They developed a risk score
based upon age, albumen, creatinine, international nor-
malized ratio, and the operative volume per center, and
demonstrated mortality in the validation cohort of 8%,
11%, and 25%, respectively, in tertiles of risk scores. This
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receiver-operating characteristic curve of 0.71. They pro-
posed that their risk score could be of value as an additional
tool in patient selection for LVAD. In an accompanying
editorial, Levy (168) pointed out that this HeartMate II
risk score is the ﬁrst prospectively validated multivariate risk
score for LVAD patients. He compared the results of this
score with several others that were available. He regretted
that the new score failed to identify both patients with too
high a risk for LVAD implantation and patients for whom
a low risk would be sufﬁcient to justify earlier application of
this therapy.
Prognostic data regarding survival is also needed for pa-
tients with hypertrophic cardiomyopathy. Therefore, Geske
et al. (169) examined the relationship between B-type
natriuretic peptide (BNP) and survival in 772 patients with
hypertrophic cardiomyopathy also undergoing clinical eval-
uation, echocardiography, and exercise evaluation. Compared
with patients within the lowest tertile of BNP values, the
3-year survival rates of patients in the second and third tertiles
were 99.2%, 94.8%, and 89.9%, respectively. Compared
with patients in the ﬁrst tertile, the HRs for death in the
second and third tertiles were 4.88 and 6.98, respectively.
Thus, BNP was shown to be an independent predictor of
morbidity and mortality in this relatively large population of
patients with hypertrophic cardiomyopathy.
Health services, quality, and outcomes research. Amer-
icans are drinking more and more coffee, with competing
cafes on seemingly every block in many downtowns. Will
America’s love affair with coffee have adverse effects on
cardiovascular disease? A review by O’Keefe et al. (170)
suggests not: daily intake of 2 to 3 cups a day appears to
be safe, and possibly even associated with beneﬁcial health
outcomes. Filtered coffee did not raise total or LDL
cholesterol levels in a small trial of young adults, although
boiled coffee did. Blood pressure may rise acutely, but long-
term BP levels do not appear to be increased with habitual
coffee consumption. Most studies of the health effects of
coffee are observational, however, so ﬁrm conclusions are not
possible.
More couples are seeking treatment for infertility, with a
consequence that there now are more multiple births. Drugs
used to stimulate ovulation have been suggested to have
adverse cardiac effects. A population-based study in Ontario,
Canada, examined the rate of cardiovascular events among
roughly 7,000 women who delivered after receiving fertility
treatment, compared with almost 1.2 million women who
gave birth without such treatment (171). The unadjusted
rate of subsequent events did not differ (103 per 100,000
person-years vs. 117 per 100,000 person-years), and multi-
variable adjustment suggested that cardiovascular risk might
even be lower after fertility treatment.
Prevention of coronary disease is a major goal, and there
are both promising trends and worrisome ones. An analysis
of NHANES (National Health and Nutrition Examination
Survey) data of representative samples of the U.S. populationbetween 1999 and 2010 by Ford (172) documented trends
toward lower rates of smoking, lower BP levels (more per-
sons were on antihypertensive drugs), and lower total
cholesterol levels. These favorable trends contrast with the
unfavorable increase in diabetes mellitus, which is presum-
ably the result of increasing obesity. Overall, the mean
predicted risk of developing coronary disease decreased in
the U.S. population from 7.2% in 1999 to 2000 to 6.5%
10 years later. This trend was not uniform across the pop-
ulation, however, with a coronary heart disease risk
decreasing signiﬁcantly only among the white population,
and not among Mexican Americans or African Americans.
The national epidemic of obesity has caused great
concern, and spurred efforts to determine whether there is
risk due from increased body mass index per se, or only from
speciﬁc metabolic consequences of obesity. Being overweight
or obese may be less important than the location and type
of fat. Abdominal obesity, as assessed by waist circumference
or waist-to-hip ratio, may be particularly important. Cou-
tinho et al. (173) studied 15,547 patients with coronary
disease from 5 studies to assess the effect of central obesity
on mortality. They report that patients with a normal body
mass index but an increased waist circumference (or waist-
to-hip ratio) had higher mortality than either patients who
were obese or patients who did not have abdominal obesity.
This study, along with others, suggests that the effects of
obesity on health are complex, and fat distribution may be
more consequential.
Variations in clinical practice often reﬂect physician
“practice style” more than differences in disease severity or
patient preferences. Follow-up testing after PCI is initiated
by physicians, and Shah et al. (174) showed that use of stress
tests in the 12 months after PCI varied widely among
hospitalsdfrom 9% to 66% of patientsddespite similar pa-
tient characteristics. One-year rates of mortality and of MI
did not vary with the use of stress tests, but rates of repeat
revascularization were signiﬁcantly higher in institutions with
higher rates of stress testingdevidence for the continued
existence of the “diagnostic-therapeutic cascade” (175).
Clinical practice variation also extends to use of medica-
tions. Aldosterone antagonists have been shown in ran-
domized trials to improve survival of patients with HF,
and have been endorsed by clinical guidelines. Between 2006
and 2009, an aldosterone antagonist was prescribed at
discharge to only 9% of 11,255 eligible patients with HF,
with only a modest increase in use over time. Among 144
U.S. hospitals that treated 10 or more eligible patients, the
use of aldosterone antagonists varied from 0% to 40% (176),
and this variation was not explained by differences in the
clinical characteristics of the patients.
Data on hospital practice patterns have been collected for
many years, but only recently have data been collected from
outpatient practices. The PINNACLE registry was recently
organized by the American College of Cardiology (ACC)
for just this purpose. An analysis of the PINNACLE data
showed that use of cardioprotective medications among
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by patient socioeconomic status (177). This variation was
no longer signiﬁcant after adjusting for practice site: where
a patient received care was a more important determinant
of medication use than his or her individual characteristics.
This ﬁnding suggests that quality improvement efforts
might focus on clinical sites that care for high proportions
of disadvantaged patients.
Randomized clinical trials are generally accepted as the
single best way to test treatment strategies, but patient
recruitment is always challenging. Martin et al. (178)
examined their institution’s experience in recruiting pa-
tients for 15 different randomized studies to identify
barriers to study participation. Trials that had many
protocol-mandated tests, and that lasted longer (6 months
or more) had signiﬁcant higher rates of patient refusal to be
randomized. Patients who would have to travel farther for
clinic visits were also much less likely to agree to participate
in trials, as were older patients and women. Pragmatic
innovations in trial design could remove some of these
barriers to participation and enhance enrollment in ran-
domized studies.
In an important paper, Masoudi et al. (179) analyzed the
data from the NCDR of the ACC to characterize the pa-
tients, measures of quality of care, and outcomes for the
5 NCDR programs. The paper presented a comprehensive
analysis of approximately 1 million patients enrolled in
5 registries, including Get with the Guidelines, CathPCI,
CARE, ICD, and PINNACLE. These important data will
provide a yardstick as well as a dashboard to assess the nature
and efﬁcacy of cardiovascular medicine in the future.
Intense exercise training may predispose to arrhythmias
such as AF. Guasch et al. (180) examined this concept in a
rat model of endurance exercise training. Rats undergoing
treadmill exercise for 1 h, 5 days a week, had an increased
susceptibility to AF (induced by programmed stimulation)
after 16 weeks, compared with 8 weeks of exercise or with
sedentary control rats. After 16 weeks of exercise training,
there was structural remodeling with left and right atrial
enlargement and ﬁbrosis. Exercise increased parasympathetic
(but not sympathetic) tone, as measured by baroreﬂex heart
rate and BP responses. There was increased sensitivity of
acetylcholine-dependent potassium current (IKAch) in iso-
lated cardiomyocytes in response to carbachol, with down-
regulation of IKACh-inhibiting regulators of G proteins
(RGS). The RGS-4 knockout mice had enhanced sensi-
tivity to AF induction, which supports a causal link.
Detraining reversed several abnormalities, but not atrial
dilation or ﬁbrosis. In an accompanying editorial, Wehrens
et al. (181) note that this study provides mechanistic in-
sights into AF with chronic vigorous exercise. Because
enhanced baroreﬂex and sensitivity to cholinergic stimula-
tion were related to down-regulation of RGS with increased
sensitivity of the IKACh channel, IKACh-channel blockers may
be beneﬁcial. Another mechanism to consider is altered
intracellular calcium cycling with increased calcium/calmodulin-dependent kinase II (CaMKII), which contrib-
utes to AF in other settings.
In a letter to the editor, Bhatti et al. (182) note clinical
evidence that autonomic imbalances and structural remod-
eling of the atria contribute to AF in humans with chronic
high-level endurance exercise. The researchers reply that in
this animal model, increased parasympathetic tone played
a key role, although atrial enlargement and ﬁbrosis may
contribute to the risk of AF as well (183).
Phosphodiesterase-2 in HF. Phosphodiesterases (PDEs)
comprise a family of enzymes that break down cyclic nu-
cleotides, cyclic adenosine monophosphate (cAMP) and
cyclic guanosine monophosphate (cGMP), which are
therapeutic targets in HF. Inhibitors of PDE3, for
example, raise intracellular cAMP levels, which is useful for
short-term positive inotropic support, but has negative
adverse effects with long-term use. Inhibitors of PDE5
raise cGMP levels to treat erectile dysfunction and pul-
monary hypertension, with potential beneﬁts in HF. Mehel
et al. (184) made the novel observation that myocardial
PDE2 expression was elevated in a small number of pa-
tients with cardiomyopathy, compared with hearts from
nonfailing donors or with AS. Rats with isoproterenol-
induced HF had increased myocardial PDE2 and cAMP
hydrolytic activity that blunted beta-adrenergic receptor
responsiveness. This was attenuated with a PDE2 inhibitor.
Overexpression of PDE2 in rat ventricular cardiomyocytes
did not alter baseline contractility, but abolished inotropic
responses to beta-adrenergic receptor stimulation. PDE2
may represent a unique target for treating HF. Kass (185),
in an editorial comment, remarked on the substrate selec-
tivity of different PDEs, which affect cAMP and cGMP
levels in different tissues and disease states. PDE2 is a dual
substrate esterase with selectivity depending on the extent
of cAMP and cGMP activation. Thus, PDE2 inhibitors
reduce the effects of excessive beta-adrenergic receptor
stimulation, while not affecting baseline contractility. This
opens a new area of research to determine whether PDE2
is beneﬁcial in human HF, without the adverse effects
associated with chronically elevated levels of cyclic
nucleotides.
In a state-of-the-art paper, Korley and Jaffe (186) discuss
how the United States should prepare for the onslaught of
high-sensitivity cardiac troponin assays. There are several
issues that are discussed in this paper. First, it becomes clear
that we need to adopt universal nomenclature that will
deﬁne uniform criteria for reference populations. We must
also learn to better discriminate between acute and nonacute
causes of high-sensitivity cardiac troponin elevations as well
as between type 1 and 2 AMI. Ruling out AMI will also take
on a new dimension. With less sensitive current assays, there
is an under-estimation of the true prevalence and an over-
estimation of the negative predictive value. The new assays
will, of course, have speciﬁc issues when it comes to high-
sensitivity cardiac troponin elevation in non–coronary oc-
clusion damage. It will also take shorter time to rule in and
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ment must be developed.
Although troponins are a benchmark for AMI, they have
been seen in many other conditions that affect the integrity
of the cardiac myocytes. High-sensitivity assays make it
possible to study normal populations and predict future
events. Because mental stress is a demonstrated risk factor
for cardiovascular disease (CVD) events, it is not surprising
that Lazzarino et al. (187) demonstrated an association be-
tween the cortisol response to mental stress and high-
sensitivity cardiac troponin T in healthy older persons. In
an accompanying editorial by Eggers (188), it is stressed that
these new assays will reﬂect not only cardiac abnormalities,
but also a risk pattern that portends the development of
abnormalities.
An important issue for patients with asymptomatic ca-
rotid stenosis is who is at risk to have an unstable plaque,
with resulting clinical events. Leukocyte-derived micro-
particles (LMPs) have been localized in plaques and are
considered to be an important component in plaque
instability. To this end, Sarlon-Bertoli et al. (189) analyzed
LMP levels using high-sensitivity ﬂow cytometry in 42
patients with high-grade carotid stenosis. They found that
higher levels of LMPs were signiﬁcantly associated with
patients with unstable plaque. As pointed out in an
editorial by Wang et al. (190), the study highlights the
clinical signiﬁcance of LMPs as promising biomarkers
associated with plaque vulnerability in patients with high-
grade carotid stenosis. What still must be answered is
whether levels of LMPs predict subsequent occurrence of
neurological events.
Recent studies have demonstrated that microribonucleic
acids (miRNAs), especially miR-133a, are up-regulated in
patients with AMI. To ascertain the release kinetics of these
miRNAs, Liebetrau et al. (191) analyzed the kinetics of the
TaqMan polymerase chain reaction in patients with hyper-
trophic cardiomyopathy who were undergoing transcoronary
ablation of septal hypertrophy, a procedure that mimics
AMI. They found that miR-1, miR-1331, and miR-208a
were continuously increased during the ﬁrst 4 h after in-
duction of MI. These results demonstrate the potential use
of these biomarkers in acute coronary syndromes. In an
accompanying editorial, Biasucci et al. (192) point out this is
promising enough that eventually these miRNAs could
represent a new gold standard for the diagnosis of MI. First,
however, we must determine how much more effective they
are than hs-troponin (hs-TN) and how speciﬁc the miRNAs
are for MI.
In a study by Heringlake et al. (193), growth differenti-
ation factor (GDF)-15 was examined as a humoral marker
for risk stratiﬁcation in patients undergoing cardiac surgery
in comparison to the European System of Cardiac Operative
Risk Evaluation (EuroSCORE). In 1,458 consecutive pa-
tients, pre-operative GDF-15 was an independent predictor
of post-operative mortality and morbidity in CABG patients
and added value beyond the EuroSCORE. Lange et al.(194), in an editorial, state that although these results are
consistent with other high-risk populations, it remains to be
determined if the incremental information gained from
GDF-15 will be useful in altering therapy and clinical
outcomes.
Eapen et al. (195) sought to determine an aggregate-
pathway speciﬁc risk score for enhanced prediction of pla-
que rupture and related death and MI in CAD patients.
They utilized 3 biomarkers reﬂecting inﬂammation (high-
sensitivity C-reactive protein), coagulation (ﬁbrin degrada-
tion productions), and cell stress (heat shock protein 70).
The predictive value of this aggregate was demonstrated
beyond established risk factors, including angiographic
score, revascularization, renal function, and ejection fraction.
In an editorial, Emdin et al. (196) pointed out that if this
proof-of-principle paper is conﬁrmed in large prospective
studies, then the possibility will exist to test whether ther-
apeutic targeting of the 3 speciﬁc pathways could be effective
therapy.
As natriuretic peptide (NP) levels continue to demon-
strate utility across the spectrum of cardiovascular disease,
further attention to their pathophysiology has been gener-
ated. Neeland et al. (197) determined that higher NP levels
were independently associated with a favorable adiposity
proﬁle, characterized by decreased visceral and liver fat and
increased lower body fat. This suggests that there is an
important link between the heart and adipose distribution,
mediated through the NP system. As Westerink et al. (198)
speculate in an editorial, perhaps there exists an adipose
tissue–derived feedback mechanism on the production of
NPs.
BNP is a useful marker in patients with HF and reduced
ejection fraction, but data for HFpEF have been scarce. Van
Velduisen et al. (199) demonstrated that although BNP
levels were found to be lower in patients with HFpEF than
in HF with reduced EF, for any given BNP, the prognosis of
patients with HFpEF was similar to those of patients with
reduced EF. In an accompanying editorial, Januzzi et al.
(200) point out that in the future, studies targeting NP levels
in HFpEF with different treatment modalities could become
a reality.
AF increases the risk of stroke and death, and thus,
prediction of risk is of vast importance. Although NPs are
often elevated in AF, Hijazi et al. (201) studied the value of
NPs in addition to established clinical scores. Their major
ﬁnding was an important one: adding N-terminal pro-brain
natriuretic peptide (NT-proBNP) levels to the CHA2DS2-
VASc score improved the C statistic for development of
stroke. In an accompanying editorial, Troughton et al. (202)
state that in patients already receiving anticoagulation
therapy for AF, a single measurement of NT-proBNP
provides powerful prediction of residual risk of stroke or
death, regardless of their CHA2DS2VASc score.
In the PONTIAC study (NT-proBNP Selected Pre-
ventiOn of cardiac eveNts in a populaTion of dIabetic pa-
tients without A history of Cardiac disease), Huelsmann
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up-titration of renin-angiotensin system antagonists and
beta-blockers in diabetic patients with elevated levels of NT-
proBNP. They found a signiﬁcant reduction in hospitali-
zation and cardiac death among the diabetic patients, with
the high NT-proBNP group treated more aggressively. An
accompanying editorial by Felker et al. (204) suggests that
studies like PONTIAC that use a single biomarker to target
or modify treatment may be the tip of an iceberg repre-
senting new paradigms in diagnosis and treatment of car-
diovascular disease.
Genetics and genomics. The best of JACC in the rapidly
growing ﬁeld of genetics and “omic” biology were chosen as
studies that signiﬁcantly impact cardiovascular health and
disease from the vantage point of a clinician-scientist.
The Copenhagen City Heart Study has contributed sig-
niﬁcant insight to our understanding of genetics, lipids, and
cardiovascular disease. Plasma lipoprotein(a) levels can vary
1,000-fold, and elevated lipoprotein(a) levels are a known
risk factor for cardiovascular disease. A paper from
Kamstrup et al. (205) that examined 8,720 subjects
demonstrated that extreme lipoprotein(a) levels or corre-
sponding risk genotypes for lipoprotein(a) (rs10455872)
improved prediction for MI and coronary heart disease. Of
the 8,720 subjects in the study, 13% were carriers for the
rs10455872 risk genotype. Notably, the rs10455872 geno-
type explained 27% of the total variation in plasma lip-
oprotein(a) levels. As pointed out by the researchers,
lipoprotein(a) levels are unique from LDL, HDL, and total
cholesterol in that the concentration distribution of lip-
oprotein(a) levels is highly skewed with a long tail toward
extreme values on the high end. A skewed distribution is
precisely what makes liproprotein(a) levels and genetics
underlying lipoprotein(a) a very hot topic of interest.
The paper by Schwartz et al. (206) provides a clear and
needed guide for incorporating genetics into the manage-
ment of long QT syndrome (LQTS), catecholaminergic
polymorphic ventricular tachycardia (CPVT), and Brugada
syndrome. The review by Schwartz et al. (206) includes
diagnostic criteria for LQTS, a review of the expert
consensus criteria, and the current understanding of the
molecular basis including the genes known to be involved in
the diseases. Cascade screening is highlighted as an impor-
tant clinical management tool to identify family members
who may be at risk for life-threatening arrhythmias. Essen-
tially, if a disease-causing mutation is identiﬁed in a patient
with LQTS, genetic testing of the family members is advised
to identify those with that speciﬁc mutation with a normal
QT interval. LQTS has a low penetrance. As pointed out by
the investigators, a normal ECG cannot be used to exclude
LQTS. This situation represents a distinct and growing area
of clinical management in which genetic testing provides a
trustworthy set of markers to improve patient care.
Clinical management of CPVT and the underlying ge-
netic mutations leading to this exercise-, excitement-, or
catecholamine-induced bidirectional ventricular tachycardiaare also reviewed. CPVT is divided into the most common,
CPVT1, as well as less common CPVT2, 3, 4, and 5. To
date, the majority of known cases of CPVT1 originate from
a heritable or a sporadic mutation in the ryanodine receptor
RYR2. Schwartz et al. (206) suggest that the main purpose
of genetic testing for the RYR2 mutations in CPVT is
diagnostic, and not prognostic or therapeutic. Genetic
testing in CPVT importantly distinguishes between the
different subtypes of CPVT (1 to 5) and may be useful in
therapy choices given that patients with CPVT associated
with speciﬁc mutations in KCNJ2 that present with complex
ventricular ectopy may be more responsive to ﬂecainide
versus beta-blocker therapy.
The clinical hallmark of Brugada syndrome is well
deﬁned, with a family history of sudden cardiac death in
20% to 50% of cases. Penetrance is low, and the pattern of
transmission is autosomal dominant and highly variable.
SCN5A remains the most prevalently associated gene
with this life-threatening syndrome with >200 mutations
described. However, >13 genes have now been associated
with Brugada syndrome. Genetic testing for these known
mutations is important in patients suspected of having
Brugada syndrome, in that a disease-causing mutation may
have an effect on lifestyle (i.e., drug therapies may have
a negative interaction).
The genetics of arrhythmogenic right ventricular cardio-
myopathy (ARVC) was chosen as a top paper this year with
the clinician in mind. Outlining the cellular abnormality
in the connections of the heart referred to as the desmosome
and leading to the pulling apart of these cell-to-cell contacts,
ARVC primarily affects the right ventricle but may also
affect the left later in the disease. ARVC is a genetic disease,
and it is inherited as an autosomal dominant trait; however,
the underlying mutations that are causative for ARVC have
only been identiﬁed in fewer than one-half of the patients.
The clinical implications of this are that a family member
that tests negative for a known genetic mutation should still
have regular examinations for ARVC. In addition, a family
member who tests positive for a known mutation associated
with ARVC but shows no clinical manifestation of the
disease should also undergo regular screening. The guide-
lines for intervals of the screening and the age at which one
can stop screening are put forth in this consensus document
(207). Questions are addressed surrounding utilizing a ge-
netic counselor as well as ethical and fundamental issues
centered on genetic screening in the diagnostic prenatal
setting, screening patients, family members, and at the time
of autopsy. The genetic screening section discusses the 5
desmosomal genetic mutations and their distribution in 2
cohorts of patients (n ¼ 52 and n ¼ 102) with ARVC.
These genes include plakophilin-2, desmoglein-2,
desmoscollin-2, desmoplakin, and junctional plakoglobin.
To date, the majority of persons with ARVC and a known
mutation present with a mutation in plakophilin-2.
A cleverly designed study from Ferguson et al. (208)
started with an enriched population of patients with CKD
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scores were used as a starting phenotype to identify genes
and pathways important in the development of atheroscle-
rosis leading to MI. Towler (209) makes 3 critical points in
the accompanying editorial to provide context around the
growing understanding of calciﬁcation and cardiovascular
risk. First, CKD imparts a greater cardiovascular disease risk
than diabetes. Second, the major metabolic insults causing
CKD also promote cardiovascular calciﬁcation, including
atherogenic diet, oxidative stress, and inﬂammation. Finally,
the cardiovascular system is the second most mineralized
structure in the human body (210). Using this cohort of
patients with CKD, Ferguson et al. (208) identiﬁed chr9p21,
COL4A1, ATP2B1, and HNF4A as mutations that were
associated with coronary artery calcium and also associated
with MI. ATP2B1 is known to play a signiﬁcant role in BP,
as it encodes a plasma membrane calcium-transporting
ATPase. Chr9p21 and COL4A1 have been deﬁned in the
past, using alternative methods and design. This approach
is likely to be replicated in several larger study designs to
leverage enriched populations.
The most widely cited paper with clopidogrel in PubMed
was the CAPRIE study (Clopidogrel versus Aspirin in Pa-
tients at Risk of ischaemic Events), a randomized, blinded
trial of clopidogrel versus aspirin in patients at risk of
ischemic events, published in 1996 (211). Since this time,
increasing awareness in the variability in antiplatelet response
per individual on clopidogrel has been recognized. This
awareness manifested itself in the form of separate factors,
including pharmacogenomics, diet, smoking, medications,
platelet assays, and biochemical pathways. This year in the
Journal, Frelinger et al. (212) designed and tested a study on
healthy subjects to determine the aspects accounting for the
variability in response to clopidogrel. The surprising
conclusion was that the known identiﬁable factors accounted
for only 18% of the variation in clopidogrel pharmacoki-
netics, strongly suggesting that our understanding of this
drug and other antiplatelet agents as well as platelet biology
and the role of platelets in multiple diseases is limited. In
healthy compliant subjects who are homozygous for
CYP2C19 and free of nicotine, alcohol, and medications,
45% of subjects had a high frequency of poor response to
clopidogrel (high on-treatment platelet reactivity). The
relative weight of genotyping was small in this model. Useful
systems biology databases have emerged in the past 10 years
to assist in enhancing our understanding of the biology. One
of these sites, available at http://www.drugbank.ca/drugs/
DB00758, links to other sites that can also be helpful.
In 2012, the Journal published a study showing a differ-
ential circulating genomic proﬁle in patients in response to
aspirin (213). This set of genes correlated with the platelet
function score and was an independent predictor for car-
diovascular events. The genes identiﬁed may help deﬁne
mechanisms and pathways underlying platelet biology. This
genomic study moves forward an important area of biology
and clinical medicine and was led by Deepak Voora. Aneditorial from Bishopric (214) helps put this in perspective
for the clinician.
Cardiac imaging. Although computed tomography angi-
ography (CTA) provides diagnostic accuracy, few data exist
regarding its prognostic value. Hadamitzky et al. (215)
developed an integrated score from CTA to improve the
prognostic value using the population of the CONFIRM
(Coronary CT Angiography Evaluation for Clinical Out-
comes: An International Multicenter) registry (n ¼ 17,793
patients, with median follow-up of 2.3 years). The results
showed that integration of the number, severity, location, and
constitution of plaques carried incremental prognostic value,
and that this composite was superior over clinical risk scores.
A meta-analysis was performed on the 4 randomized,
controlled trials (3,266 low-risk patients) comparing emer-
gency department triage including CTA (n ¼ 1,869) versus
usual care (n ¼ 1,397) (216). Meta-analysis revealed no
differences between the 2 approaches in incidence of
infarction, post-discharge visits to the emergency depart-
ment, or rehospitalizations. All studies demonstrated a sig-
niﬁcant reduction in length of stay with CTA, and 3 of 4
studies showed a reduction in costs. The absence of CAD on
CTA was associated with excellent prognosis and facilitates
patient management (with earlier discharge). Conversely,
when CTA demonstrates (obstructive) CAD, the optimal
management is still to be determined. Triage including
CTA revealed a slight increase in invasive coronary angi-
ography (8.4% after CTA vs. 6.3% after usual care) and
subsequent revascularization (4.6% after CTA vs. 2.6% with
usual care). As Weigold (217) pointed out in an accompa-
nying editorial, the precise implications of these ﬁndings are
unclear and need further study. It is important to better
understand the vulnerability and also the functional signiﬁ-
cance (ischemia or not?) of the stenosis (beyond the stenosis
severity) to better target the therapy.
Versteylen et al. (218) demonstrated that semiautomated
plaque quantiﬁcation provided additional prognostic value
for the development of acute coronary syndromes as
compared with visual analysis of CTA. Of 1,650 patients
who underwent 64-slice CTA, 25 had an acute coronary
syndrome over the next 26  10 months. These patients had
higher total and noncalciﬁed plaque burden and larger
remodeling index as compared with 101 control patients
with CAD on CTA who did not have an acute coronary
syndrome. These observations suggest that quantiﬁcation of
lesions on CTA may help in identiﬁcation of vulnerable
lesions (219).
Other novel CT technology allows for integrated assess-
ment of coronary stenosis (CTA) and myocardial perfusion.
Rief et al. (220) applied this approach in 91 patients with
previous stent implantation to evaluate potential in-stent
restenosis and its hemodynamic signiﬁcance. Speciﬁcally,
if the CTA was nondiagnostic, CT perfusion was added.
Using quantitative coronary angiography as the gold standard,
the integration of CTA and perfusion yielded a superior
diagnostic accuracy per patient as compared to CTA alone
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grating coronary anatomy with hemodynamic consequences
(impaired perfusion) for assessing in-stent restenosis (221).
Another approach to assess the hemodynamic signiﬁcance
of a stenosis with CT is assessment of the contrast gradient
attenuation along a coronary arterial lesion, or transluminal
attenuation gradient, as reported by Wong et al. (222) using
320-row detector CT. This approach was compared with
invasive angiography and fractional ﬂow reserve assessment
in 54 patients, and yielded a good agreement. Einstein (223)
pointed out that further (diagnostic and prognostic) studies
are needed to deﬁne the clinical value of transluminal
attenuation gradient.
There is also an increasing interest in hybrid imaging,
such as positron emission tomography (PET)/CT. For
example, PET/CT with F18-ﬂuorodeoxyglucose (FDG)
may improve diagnosis in cases of suspected prosthetic valve
endocarditis (224). The addition of increased perivalvular
FDG uptake to the modiﬁed Duke criteria improved the
diagnostic accuracy to 76%.
The prediction of symptomatic embolism in infective
endocarditis is difﬁcult, but the risk could be quantiﬁed by
the use of a risk calculator including age, diabetes, AF,
embolism before antibiotics, vegetation length, and Staph-
ylococcus aureus infection (225). This approach was developed
in a derivation population (n ¼ 565) and performed well in
a subsequent validation population (n ¼ 282), contributing
signiﬁcantly to the 6-month prediction of emboli.
Cardiac CT imaging can also be used for assessment of
body fat. Britton et al. (226) evaluated the relation between
body fat distribution on multidetector row CT and outcome
in 3,086 participants from the Framingham study. The body
fat distribution included visceral, pericardial, and periaortic
adipose tissue. At a median of 5 years of follow-up, 90 car-
diovascular events were noted, and there were 141 cancer
events and 71 deaths. Visceral adiposity was associated with
cardiovascular disease and cancer, but not with all-cause
mortality.
In the Heinz Nixdorf Recall study, 4,093 participants
without cardiovascular disease underwent electron beam CT
for assessment of coronary artery calcium; follow-up of 8.0
years was obtained (227). From these scans, epicardial adi-
pose tissue could also be quantiﬁed. Epicardial fat volume
was associated with cardiovascular risk factors and coronary
artery calcium. Furthermore, epicardial fat was associated
with fatal and nonfatal coronary events during follow-up,
independent of risk factors. Also, epicardial fat volume
provided incremental prognostic information over coronary
artery calcium. The pathophysiological mechanism linking
epicardial fat with prognosis is currently unclear (228).
The effect of statin therapy on epicardial adipose tissue
was further assessed in the BELLES (Beyond Endorsed
Lipid Lowering With EBT Scanning) trial (229). In 420
hyperlipidemic post-menopausal women, moderate (pra-
vastatin 40 mg/day) or intensive (atorvastatin 80 mg/day)
lipid-lowering therapy was administered during 1 year;patients underwent electron beam CT at baseline and 1 year.
LDL decreased by 53.3% with atorvastatin and by 28.3%
with pravastatin. Epicardial fat volume at baseline
correlated with risk factors and coronary artery calcium; a
signiﬁcant reduction in epicardial fat occurred with
atorvastatin, but not with pravastatin. Importantly, the
reduction in epicardial fat was not related to the reduction
in LDL. This may be related to other effects of statin
therapy (such as inﬂammation reduction) (230).
CT has also been used to evaluate aortic valve calciﬁca-
tion, particularly in the diagnostic work-up for potential
TAVR (231). Often, a discordance between the mean
gradient and the calculated aortic valve area exists on
echocardiography. In 646 patients with normal LV function,
echo Doppler echocardiography and CT (valve calcium
score) were performed; 186 patients showed disagreement
for AS severity, almost always due to a small aortic valve area
(<1.0 cm2), but with a low mean gradient (<40 mm Hg). In
these patients, CT (calcium score) can help to differentiate
as severe aortic valve disease is virtually always associated
with severe valve calciﬁcations. Further studies comparing
the echocardiographic and CT ﬁndings with histology (e.g.,
during valve replacement) and follow-up are needed (232).
It has recently been realized that patients with cancer are
at great risk for the development of heart disease due to the
cardiotoxicity of novel chemotherapeutic agents. In 2013,
the Journal published 2 of the most important original
clinical research papers. The OVERCOME trial (preven-
tiOn of left Ventricular dysfunction with Enalapril and
caRvedilol in patients submitted to intensive ChemOtherapy
for the treatment of Malignant hEmopathies) (233), a
randomized controlled study including 90 patients with
recently diagnosed leukemia or with malignant hemopathies
undergoing autologous stem cell transplantation showed that
combined treatment with enalapril and carvedilol may pre-
vent LV systolic dysfunction. Moreover, compared with
control patients, patients in the intervention group had a
lower incidence of the combined event of death and HF
(6.7% vs. 22%; p ¼ 0.03) as well as of death, HF, or a ﬁnal
LV ejection fraction <45% (6.7% vs. 24.4%; p ¼ 0.02). The
results of this trial were discussed in an accompanying
editorial by Smiseth et al. (234). Moreover, a paper by
Ylanen et al. (235) studied 62 long-term survivors of
childhood cancer who had been exposed to anthracycline at
a mean age of 14.6 years. The researchers concluded that
a considerable proportion of these patients demonstrated
cardiac dysfunction by MRI with involvement of both
ventricles in the absence of replacement myocardial ﬁbrosis
deﬁned by late gadolinium enhancement 7.8 years after
anthracycline exposure.
Among the best papers this year is the intriguing ran-
domized, double-blind, placebo-controlled trial conducted
in 66 patients with ischemic heart disease by Rekhraj et al.
(236) demonstrating that high-dose allopurinol regresses
LV hypertrophy, reduces MRI-deﬁned LV end-systolic
volume, and improves endothelial function in patients with
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signiﬁcantly reduced the LV mass index (2.2  2.78 g/m2)
versus placebo (0.53  2.5 g/m2; p ¼ 0.023). The ﬁndings
are further discussed from the perspective of what is known
in terms of xanthine oxidoreductase metabolism and nitroso-
redox imbalance vis à vis LV structure and function by Kar-
antalis et al. (237) in an accompanying editorial comment.
Two comprehensive papers review and further extend the
use of cardiovascular MRI to assess cardiovascular prognosis.
In the ﬁrst, Lipinski et al. (238) add an important meta-
analysis to the literature on the prognostic value of stress
MRI in patients with known or suspected CAD. Nineteen
studies involving 11,636 patients are included in the analysis
with a mean follow-up of 32 months. The researchers
observed that negative stress cardiac magnetic resonance
(CMR) is associated with a very low risk of cardiovascular
death and MI. Patients with ischemia by stress MRI had
a higher incidence of MI (OR: 7.7; p < 0.0001), cardio-
vascular death (OR: 7.0; p < 0.0001) compared with pa-
tients who had a negative study. In a second paper, Saam
et al. (239) identiﬁed 8 studies that included 689 patients
who underwent carotid MRI studies to assess the extent and
composition of atherosclerotic plaques. Over a median
follow-up of 19.6 months, a total of 108 cerebrovascular
events occurred, and the presence of intraplaque hemorrhage
was associated with an approximately 6-fold higher risk
for events (HR: 5.69; 95% CI: 2.98 to 10.87). The annu-
alized event rate in subjects with detectable intraplaque
hemorrhage was 17% compared with 2% in patients without
it. In a third clinically prospective study, Kubanek et al.
(240) reported novel predictors of LV reverse remodeling by
MRI in patients with recent-onset dilated cardiomyopathy.
From a total sample of 44 patients, 20 experienced reverse
remodeling at 12 months. At baseline, lesser amounts of
replacement ﬁbrosis quantiﬁed by MRI late gadolinium
enhancement (OR: 0.67; p ¼ 0.008) and greater extent of
myocardial edema (OR: 1.45 [95% CI: 1.04 to 2.02]; p ¼
0.02) were independent predictors of reverse remodeling. At
3 months, however, BNP plasma level was the strongest
predictor of reverse remodeling in the same patients (OR:
0.14, p < 0.04). An accompanying editorial by Friedrich
(241) discusses the state-of-the-art utilization of cardiovas-
cular MRI for the assessment of myocardial injury in pa-
tients with dilated cardiomyopathies.
Myocardial perfusion quantiﬁcation by PET has become
the clinical reference standard. Naya et al. (242) reported the
prognostic interplay of coronary artery calciﬁcation and its
underlying vascular dysfunction in patients with suspected
CAD. Of 901 patients who had undergone 82Rubidium
myocardial perfusion imaging by PET and coronary artery
calciﬁcation (CAC) scan by CT, all patients had normal
myocardial perfusion imaging clinically. The researchers
reported that global coronary ﬂow reserve (CFR) provided
signiﬁcant incremental risk stratiﬁcation over clinical risk
scores for prediction of major events including cardiac death,
MI, late revascularization, and admission for congestive HF.While CFR decreased progressively with increasing levels of
CAC from 2.25 to 1.88 (p < 0.0001) over a median follow-
up of 1.53 years, PET CFR but not CAC by CT was
predictive of events over and above clinical variables.
In 2013, a feasibility study by Tawakol et al. (243) using
FDG PET to examine the consequences of intensifying
statin therapy for rapid reduction of atherosclerotic inﬂam-
mation in 83 patients was reported, leading to an increased
interest in the utilization of this method to evaluate plaque-
related inﬂammation. Twelve weeks after the onset of ther-
apy, inﬂammation measured as the target-to-background
ratio of FDG uptake in the index vessel was signiﬁcantly
reduced from baseline in patients taking atorvastatin 80 mg
(14% reduction, p < 0.001), but not in patients randomly
assigned to atorvastatin 10 mg (4.2% reduction, p > 0.1).
Target-to-background ratio reductions compared to baseline
were seen as early as 4 weeks after atorvastatin therapy, which
did not correlate with lipid proﬁle changes. The investigators
concluded that statin therapy produced signiﬁcant rapid
dose-dependent reductions in FDG uptake that could reﬂect
a decrease in atherosclerotic plaque inﬂammation. The
methodological aspects of this new technology and its
implication for assessing inﬂammation in atherosclerosis are
discussed by Gerber (244) in an accompanying editorial
comment.
Among other imaging studies with potential for short-
term clinical application, the paper by Ahn et al. (245) re-
ports the risk stratiﬁcation of patients undergoing
intermediate-risk noncardiac surgery using CT coronary
angiography. Among a total of 239 patients, 19 (8%) had
post-operative cardiac events. In addition to the revised car-
diac risk index score, which did correlate with events as ex-
pected (p < 0.0001), CAC (p < 0.001), presence of
signiﬁcant (>50% stenosis) CAD, and multivessel CAD
(p < 0.001) were also correlated with the occurrence of car-
diovascular events. Predictive models based on C statistics
showed that the revised cardiac risk index score plus CAC
and multivessel CAD were more powerful than the revised
cardiac risk index score alone to assess prognosis in this group
of patients. An editorial by Richard (246) discusses the results
of this provocative study in the assessment of pre-surgical risk.
Among publications exploring the use of CMR to char-
acterize less explored frontiers in cardiovascular phenotyp-
ing, Karamitsos et al. (247) conducted a pilot study of
27 patients with overt hypertrophic cardiomyopathy, 10
mutation carriers without hypertrophy of the left ventricle,
11 athletes, and 20 healthy controls who were imaged by
3-T CMR. In addition to myocardial function and perfu-
sion, myocardial oxygenation assessed as the blood-oxygen
level dependent change in signal intensity under adenosine
stress was obtained. The myocardial perfusion reserve index
was signiﬁcantly reduced in patients with hypertrophic car-
diomyopathy (1.3) compared with controls (1.8; p < 0.001)
and athletes (2.0; p < 0.001) but was within normal range in
mutation carriers (1.7; p ¼ 0.61). Conversely, myocardial
oxygenation was altered not only in patients with
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carriers (10.4%) compared with controls and athletes (18.9%
and 18.7%; p < 0.001 and p < 0.003, respectively). The
study was thought provoking, with potential pathophysio-
logic implications for how the hypertrophic phenotype de-
velops among persons who are genetically predisposed to
hereditary hypertrophic disease.
A study by Hayashi et al. (248) utilized the washout of
99mTc-sestamibi to assess mitochondrial function in patients
with dilated cardiomyopathy. In that study, 20 patients with
NYHA functional class I to III were studied with nuclear
scintigraphy but also underwent cardiac catheterization with
coronary angiography and myocardial biopsy. The washout
rate of 99mTc-sestamibi was signiﬁcantly correlated to a
reduction in rate of rise of LV pressure (dp/dt), reﬂecting
depressed myocardial contractile behavior, in addition to a
reduction in the abundance of mitochondrial ribonucleic acid
and an increase in the severity of mitochondrial damage
detected by electron microscopy from myocardial biopsies
obtained at the time of cardiac catheterization. The study’s
importance in terms of clinical pathophysiologic investigation
was discussed by Strauss (249) in an editorial.
To assess the reproducibility of echocardiography to
detect the cardiac effects of cancer chemotherapeutic agents,
Marwick et al. (250) examined a series of breast cancer
patients undergoing chemotherapy in whom global longi-
tudinal strain measurements at 5 time points from 3 to 12
months were stable so that changes in ejection fraction could
be taken as an index of reproducibility of the measurement.
The 2 and 3-dimensional (3D) studies in 56 patients
showed that noncontrast 3D ejection fraction, end-diastolic
volume, and end-systolic volume had signiﬁcant lower
temporal variability than all other methods. Contrast was
of value primarily in the 2-dimensional echocardiography
method. The data from this study indicated that a temporal
variability of ejection fraction of 0.06 might be achieved with
3D echocardiography. These data should be of great value
applying ultrasound to follow patients receiving cancer
chemotherapy. In an accompanying editorial, Mor-Avi and
Lang (251) commented that the major importance of this
study is that it provides the critically needed scientiﬁc evi-
dence to support routine clinical use of 3D echocardiography
to monitor adverse events of cancer chemotherapy.
Myocardial contrast echocardiography (MCE) has
showed considerable promise in recognizing myocardial
ischemia, but large randomized trials have been few. This
year Senior et al. (252) presented data of a randomized
clinical trial comparing sulfur hexaﬂuoride microbubble
(SonoVue, Bracco Imaging, Courcouronnes, France)–
enhanced MCE with gated single-photon emission
computed tomography (SPECT) for detection of signiﬁcant
CAD. They studied 628 patients gathered at 34 centers
using rest/vasodilator enhanced ﬂash-replenishment MCE
and 99mTc-labeled SPECT. The MCE demonstrated
higher sensitivity than SPECT (75.2% vs. 49.1%; p <
0.0001) although speciﬁcity was lower (52.4% vs. 80.6%,respectively; p < 0.0001) for 70% stenosis. Thus, this well-
done study, which utilized coronary angiography as an in-
dependent gold standard, showed that MCE was generally
comparable to SPECT, showing higher sensitivity but lower
speciﬁcity. In an accompanying editorial, Thomas (253)
observed that the diagnostic accuracy for coronary disease
of both MCE and SPECT were relatively modest when
compared to coronary angiography. He believed that,
although the results were encouraging for the application of
MCE, they were still not sufﬁcient to justify immediate
application of this technique in clinical practice.
Flurpiridaz F18 is a new diagnostic agent for PET
myocardial perfusion imaging. Therefore, Berman et al.
(254) conducted a phase II trial comparing ﬂurpiridaz
F18 with Tc-99m SPECT in 143 patients from 21 centers.
In patients who underwent coronary angiography, the
sensitivity of PET was higher than SPECT (78% vs. 61%;
p < 0.02). Speciﬁcity was not signiﬁcantly different.
Receiver-operating characteristic curve areas were 0.82 for
PET and 0.70 for SPECT (p < 0.04). Thus, this trial
showed that PET myocardial perfusion with ﬂurpiridaz
F18 was superior to SPECT for overall diagnosis of CAD.
In a continuing effort to establish the clinical beneﬁt of
MCE, Porter et al. (255) compared MCE to conventional
stress echocardiography in which contrast was used to opti-
mize wall motion abnormalities with the outcome of death or
nonfatal MI in patients with intermediate to high pre-test
probability. Left ventricular opaciﬁcation with contrast was
applied only in technically suboptimal studies. An abnormal
MCE was more frequently observed than an abnormal con-
ventional stress echocardiogram and resulted in a greater
number of revascularizations. Resting wall motion abnor-
malities were more frequently seen with MCE and were an
independent predictor of death or fatalMI (p¼ 0.005). These
data demonstrate that, in a typical population, perfusion im-
aging withMCE yields a higher sensitivity of CAD detection
in patients who are more likely to undergo revascularization.
In an important substudy from the STICH trial (Surgical
Treatment for IsChemic Heart failure), Panza et al. (256)
examined whether the presence of inducible myocardial
ischemia would predict outcomes in patients with CAD and
LV dysfunction. Of 399 patients who underwent either
radionuclide stress test or dobutamine stress echocardiog-
raphy, one-half were randomly allocated to either CABG or
medical therapy. There was no signiﬁcant difference in all-
cause mortality between patients who manifested ischemia
and patients who did not, nor was there an interaction be-
tween the presence of ischemia and treatment that was
administered. The investigators concluded that in patients
with coronary disease and severe LV dysfunction, inducible
myocardial ischemia did not identify patients with either a
worse prognosis or greater beneﬁt from either medical
therapy or surgical revascularization. In an accompanying
editorial, Gibbons and Miller (257) opine that although this
STICH substudy did not provide evidence supporting a role
for stress-induced ischemia in selecting patients who would
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the nature of the patients included in the trial, the data
cannot be considered to establish a lack of beneﬁt of stress
test exhibited myocardial ischemia.
Congenital heart disease. Teun van der Bom et al. (258)
examined the impact of systemic right ventricle in a multi-
center study from the Netherlands. Eighty-eight patients
with a mean age of 33 years were includeddthey had
congenitally-corrected transposition (28%), or other condi-
tions with systemic right ventricle. RV end-diastolic volume
index was determined by CT or CMR. The ﬁndings
were that patients with an end-diastolic volume index
>150 m/m2 and a peak exercise systolic BP <180 mm Hg
had a 20-fold higher event rate. The suggestion was that
both exercise testing and CMR or CT imaging are impor-
tant for assessing risk for adult congenital patients with
systemic right ventricle.
In a study from theMayo Clinic, the investigators reviewed
819 patients who, between 1946 and 2005, had isolated
coarctation and underwent primary repair (259). Mean age
was 17.2 years, and 83% had pre-operative hypertension. A
variety of repair techniques were includeddend-to-end an-
gioplasty was most common. The mortality rate was quite
low. Actuarial survival rates were 93.3% at 10 years, 86.4% at
20 years, and 73.5% at 30 years. The conclusions were that
the primary repair had low mortality, whereas long-term
survival was reduced compared to normal. These ﬁndings
suggest the need for earlier identiﬁcation and earlier inter-
vention in patients with simple coarctation.
In a follow-up study of patients who had Kawasaki disease
between 11 and 29 years of age with onset >12 months
before the study visit, there were 203 study and 50 control
patients (260). The ﬁndings were that patients had higher
peak velocity in the left common carotid artery and higher
pulsatility, with no differences in endothelial function or
carotid intima-media thickness stiffness. Patients with
maximum diameter after Kawasaki that was either normal or
mildly ectatic still had normal vascular health issues. In an
editorial comment, Burns and Daniels (261) emphasize that
the majority of children are likely to have minimal or no
detectable changes in their vascular health and that this
represents a relatively clean bill of health but requires normal
continuing follow-up.
A paper from the Netherlands and Canada reviewed the
Quebec congenital heart disease and Dutch CONCOR
(CONgenital CORvitia) databases to identify patients ages
18 to 65 years who were hospitalized between 1996 and
2005 (262). The researchers studied 30-day in-hospital
mortality of men and women followed up for adult
congenital heart disease diagnoses, and of women with and
without history of pregnancy. There were 54,195 hospital
admissions, 62% (33,000) of them for womend28% of the
women’s admissions were pregnancy related. Mortality was
higher for men than for women, especially for those between
18 and 45 years of age, even after adjustment for pregnancy.
The conclusions were that, for patients with congenital heartdisease from 18 to 45 years of age, 30-day in-hospital
mortality for nonpregnancy admissions was lower for
women than for men. In fact, it was lowest among women
with a pregnancy historydwhich was not associated with a
higher cardiac surveillance and higher use of hospital visits.
There appears to be a protective effect of sex in women with
congenital heart disease of reproductive age neither associ-
ated with nor requiring increased surveillance.
A cast of major experts in sports medicine and hypertrophic
cardiomyopathy point out that congenital heart disease is still
the most common cause of sudden death in the young,
especially among athletes (263). The study followed up 224
patients with implanted cardiac-deﬁbrillators. The biggest risk
factor was extreme LV hypertrophy, and these patients were
the most likely to have shocks. Forty-three patients received
>1 appropriate shock. There were ICD-related complica-
tions, inappropriate shocks, and lead malfunction in 91 pa-
tients. The ﬁndings support the current risk stratiﬁcation for
patients with hypertrophic cardiomyopathy susceptible to life-
threatening arrhythmias and underscore the important role of
prevention with ICDs, even though ICD-related complica-
tions can be expected in this population. In an editorial
comment, Sherrid (264) reviewed several cases from his own
experience, and re-emphasized the importance of patients
having ICDs despite the risk of inappropriate shocks.
A study from London compared pre- and post-Fontan
RV anatomy and phase-contrast ﬂow distribution in 58 pa-
tients studied serially by MRI (265). The researchers found,
as expected, that serial MRI showed the adaptation of the
systemic RV with Fontan completion, volume reduction,
and preserved stroke volume, and, importantly, increased
ejection fraction. The index of left and right pulmonary ar-
tery cross-sectional dimensions increased after Fontan. The
completion of the hemi-Fontan showed improved RV
function and decreased RV volumes, but was a risk factor for
decreased left pulmonary artery growth. The researchers
concluded that this may be due to the condition itself, and
no other factors in terms of the timing of the Fontan or RV
function had an impact on reduced pulmonary artery growth.
Left pulmonary stenosis is, in fact, a problemdthe ﬂow
dynamics from the arterial shunt into the right pulmonary
artery, directing most of the ﬂow to the right lung, and the
superior vena cava to right pulmonary artery shunt, of course,
also showed a correlation of vena cava and RV size.
A somewhat controversial paper from Melbourne reviews
123 (35 female, 85 male) neonates (age >30 days) and
infants (ages 31 days to 1 year) undergoing intervention
for congenital AS (266). By multivariate analysis, balloon
valvuloplasty as treatment for neonates was predictive of the
need for reintervention. Thirty-ﬁve patients ultimately needed
valve replacement. Surgical valvuloplasty provided better
results than balloon aortic valvuloplasty; however, balloon
valvuloplasty could, of course, delay the need for surgery.
A paper authored by a number of expert clinicians and
surgeons on behalf of the ACC Adult Congenital and Pe-
diatric Cardiology Section reviews tetralogy of Fallot from
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3% (267). The investigators point out that cardiac MRI is
the gold standard for imaging RV function, RV outﬂow
tract, pulmonary arteries, and collaterals. After repair, atrial
re-entrant tachycardia will develop in >30%, and a high-
grade ventricular arrhythmia will develop in 10%. Sudden
death is uncommon. Deﬁnitive information about ultimate
surgical strategies or primary repair to preserve RV function
and reduce arrhythmias is still lacking. Post-operative lesions
are often amenable to surgical transcatheter intervention,
including pulmonary valve replacement or transvalve inser-
tion. Ongoing surveillance is critical for RV functiondonce
clinical RV dysfunction develops, there are no medical
therapies that have been shown to be effective except for
resynchronization with biventricular pacing. For patients
with signiﬁcant pulmonary regurgitation and RV dilation,
the optimal timing for pulmonary valve replacement remains
uncertain. Tetralogy of Fallot is one of the most common
major surgical diseases, and appears treatable, but patients
post-operatively require close surveillance with MRI, which
is probably the best way of following RV function.
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